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INTRODUCTION

Metastasis is the complex process in which tumor cells
growing at a primary site detach from the primary tumor, migrate
throughout the body, invade into normal tissue at a distant site,
and grow into secondary tumors. The process of blood-borne
metastasis is one of the major obstacles to the treatment of
cancer, and is illustrated in a general and very simplified
fashion in Figure 1. The tumor must first invade through normal
tissue until it reaches a circulatory system, or, as illustrated,
can induce the formation of its own supply of blood vessels. Tumor
cells must then migrate through the basement membrane surrounding
the vessel in order to be released free in the circulation
(intravasation). The cells must then survive transport in the
circulation throughout the body, and attach at some distant site.
Here the tumor cell or cells must again penetrate the endothelium
and basement membrane (extravasate) and migrate into the normal
tissue, where the process of growth, invasion, and metastasis
begins again. It has been estimated that only a very small
percentage of tumor cells released into the circulation actually
survive this process and develop into secondary growths. Many
investigators are studying the mechanisms which allow certain
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Figure 1. The pathogenesis of metastasis (from Fidler, 1978).
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tumor cells to successfully complete the difficult metastatic
pathway in the hope of finding ways to interfere in this process.
Recently researchers have tried to identify phenotypic
properties necessary for metastasis by comparing normal cellular
properties to those of transformed cells from the same tissue or
by comparing the properties of tumor cells from the same origin
with different metastatic potential. In this way, it has been
demonstrated that there is a good correlation between an increase
in proteolytic activity and an increase of the metastatic
capability of certain tumor lines. As more information about the
types of proteolytic enzymes secreted by tumor cells became
available, roles for their possible involvement in the metastatic
process were postulated. Due to the complex nature of the
metastatic process, especially with regards to the number of
interactions between a metastasizing tumor cell and the host,
(i.e. immune system, hormones and growth factors, plasma proteases
and inhibitors, etc.)

there have been many suggested points of

protease action, some of which have been in direct contradiction.
The process of metastasis can be conveniently divided into several
distinct steps as illustrated in Figure 1, although it should be
understood that tumors are heterogeneous and not all tumor cells
need to complete all of the steps in order for metastasis to
occur. Proteases have been proposed to be involved in many of
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these steps and there is evidence to support these ideas. Two of
the major functions which proteases may perform are the
degradation of normal host tissues which would act as barriers to
a migrating tumor cell, and the reattachment of the tumor cell
after it is in circulation.

For example, plasminogen activators

can activate the serum enzyme plasminogen to plasmin, a general
serine type protease which can degrade many proteins on the
surface of normal cells and attack many extracellular structures
such as fibrin and fibronectin. Plasmin has also been shown to
activate latent collagenase, a metalloproteinase which is
essential for complete degradation of the basement membrane. It
has been demonstrated that some tumors secrete a type IV
collagenase and this proteinase may also be a part of the
successful metastatic cell's phenotype. Cathepsins, especially B,
have been shown to correlate in some cases with metastatic
potential, and they too can degrade a variety of substrates,
including proteoglycans and type IV collagen by activation of
latent collagenase. In addition, other proteases, such as
elastase, cathepsin D, and neutral trypsin-like proteases, have
been correlated with metastatic potential. These may again be
involved in degradation of normal host tissue. Thrombin has been
postulated to play an important role in the reattachment of tumor
cells by converting fibrinogen to fibrin and thus creating a

5

fibrin clot.

Many tumors have been shown to secrete factors which

activate thrombin, and factors which stimulate platelet
aggregation have also been isolated. This can lead to the
aggregation of a tumor cell and platelets or other blood
components. An embolus formed by clumping of tumor cells,
platelets and fibrin would help to anchor the tumor cell at a
secondary site where it can invade to form a new tumor.
Other suggested roles for proteases include, 1) defensive
mechanisms against the host immune system, 2) facilitating the
release of tumor cells from the primary tumor by decreasing cellcell adhesion, or 3) modification of the cell surface of adjacent
normal cells. Modification of cell surfaces can stimulate the
secretion of growth factors or proteinases by the normal cells
which are necessary for the tumor to metastasize. These factors
may also be important to the process of angiogenesis, which is
another important feature of the progression of some tumors.
Although much evidence has accumulated over the years in
favor of a crucial role for proteinases in the metastatic process,
the issue is still not clearly resolved. Many of the results
consist mainly of correlations with little direct evidence. In
other cases the literature is contradictory, or at best unclear,
perhaps because of the many different model systems and types of
tumors being studied.
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If proteases are essential to the process of metastasis, it
may be possible to inhibit the spread of cancer by inhibiting the
proteases involved. Alternatively, since much of the current
literature disagrees on the importance of proteases in the process
of metastasis, it may be possible to determine if specific
proteases are necessary for metastasis by inhibiting their action.
However, the inhibition of individual proteases in an .in.

.Y1YQ_

model for tumor metastasis presents several problems. Some of the
most potent enzyme inhibitors (i.e., chloromethylketones) are very
toxic .in.

yj.yQ_.

Other inhibitors lack the specificity required to

inhibit a particular enzyme or type of enzyme, thus producing
results which are not conclusive. In addition, concentrations of
the inhibitors must be able to be maintained at high enough levels
to significantly inhibit the protease in order for an effect to be
observed. Several .in. vitro models have been developed to
selectively examine steps or stages in the metastatic process, and
these have yielded valuable information. However, as noted above,
the overall process of metastasis is very complex, and
observations made .in. vitro may not be directly relevant to the .in.
.v.i.vQ situation.

The goal of this dissertation was to further investigate the
role of proteolytic enzymes in metastasis utilizing specific
enzyme inhibitors. Some of these enzyme inhibitors have been newly
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synthesized in this and other laboratories, and should allow for
the specific inhibition of implicated proteases. By performing
these studies in a relevant in .Yi.Y.Q.. model system, it is hoped that
these results will help to clarify the importance of proteinases
in metastasis and hopefully lead to a better understanding and
treatment of neoplastic disease in the future.
The specific aim of this work therefore, was to examine the
role of the proteolytic enzymes cathepsin B, plasminogen
activator, and thrombin in the process of metastasis by inhibiting
their activity in an in .Y.i.YQ. model system for metastasis. It was
proposed to accomplish this goal by treating the experimental
animals with specific proteolytic inhibitors. Because of the
evidence suggesting that plasminogen activator is important to the
process of metastasis, and because there exist different types of
plasminogen activators with different properties, a second aim of
this project was to identify and characterize the plasminogen
activator(s) produced by the tumor used in the in .Yi.Y.Q. model.

LITERATURE REVIEW

1. GENERAL DISCUSSION OF PROTEASES IN METASTASIS

Although the role of proteases in metastasis has become a
very active area of research over the past decade, there are still
very few clear conclusions to be found in the literature, which is
now quite extensive in this area ( Strauli

~.al..,

1980; Liotta

and Hart, 1982; Quigley, 1979a; Nicolson, 1982; Schirrmacher,
1985). This is due in a large part to the complexity inherent in
the metastatic process and therefore in any attempts to study it.
It is also due in part to the large variations between
investigators in the type of tumors studied and the model systems
and methods used to investigate them.
Much of the evidence which supports the theory that increased
production of proteases is an important component of a tumor
cell's metastatic potential comes from simple quantitative
experiments. Many of the earliest experiments compared the amount
of certain proteases produced by a tumor with the amount produced
by normal tissue. For example, Recklies

~.al_.

(1980) demonstrated

that explants of malignant human breast tissue maintained in
tissue culture secreted 10-fold greater amounts of cathepsin B
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than did similarly maintained explants of normal tissue or
fibroadenoma. It is interesting to note that in this study, the
authors detected no difference in the amounts of plasminogen
~

activators (PA), collagenase, or cathepsin D. However, Evers

.ai.. (1982) report a 4-fold increase in PA activity in human breast

tumors compared to normal tissues. Similarly, Keiditsch and
Strauch (1970) showed that mammary carcinomas display a higher
level of collagenase activity in the periphery of the tumor than
in the central regions, both of which were higher than normal
surrounding tissue. Among the many explanations for this
contradiction in the reported levels of proteinases in breast
tissue, several deserve comment. First, one study (Recklies

~

.al.., 1980) maintained the tumor in tissue culture for at least two

days before assaying for proteinase. The question of whether tumor
cells .1n yitro are suitable models for .1n.v.iv2. tumors depends on
the question asked, but is probably most suitably answered in the
negative. In addition, differences in the preparation of the
samples, the assays used for plasminogen activator, the size and
stage of the tumor growth and the presence of normal host cells
and/or proteinase inhibitors make interpretation of any study
using tumor tissue difficult. Two of these authors also compared
the amounts of protease secreted by primary tumors and metastases;
Recklies

~~.

(1980) finding one third the amount of cathepsin B
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in metastasis and

Evers~ .al_.

(1982) finding no significant

difference in PA levels. These early observations are significant
in light of experiments performed by

Colombi

~.al.

(1984) which

demonstrate a very high level of PA activity in adenocarcinoma
tissue, but very low levels of plasma PA activity in patients
bearing metastasis. The authors suggest that the tumor secretes
high levels of PA in the peritumor space to degrade normal tissue,
but once in the circulation, decreased levels of PA increase the
chances of the tumor attaching by means of a fibrin clot, and
hence increases the chance of metastasis. This illustrates that
certain tumor cells may vary the secretion of proteases depending
on their environment, or that more than one of the heterogeneous
cell populations found in a tumor may act in a concerted manner
to produce metastasis. There are many other reports in the
literature which quantitate the amount and type of protease in
tumor samples and compare it to that found in normal tissue, or
compare the proteases secreted by malignant tumors with the
proteases secreted by nonmalignant tumors of the same type
Wilson and Dowdle, 1978; Wilson

~.al..,

1980; Kirchheimer

~

(i.e.,

.aJ....,

1985; Sloane and Honn, 1984). In the majority of these, a positive
correlation between the invasive state and protease production is
observed. In some cases this correlation is not observed, but
because of the problems with obtaining homogeneous samples of
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tumor tissue, free from contaminating normal cells, proteases, or
inhibitors, these results can all be questioned.
An interesting method to overcome some of these problems is
to use labeled probes (radioactive or fluorescent antibodies or
inhibitors) directed against the protease under study, and examine
fixed sections of tumors, where the normal cells can be clearly
identified.

Recently, urokinase (UK) has been localized in Lewis

Lung tumors to areas of invasive growth and degradation of normal
tissue using antibodies directed against the enzyme (Skriver

~

.a.J...., 1984). This method has also been used to look at the amounts
and location of proteases on tumor cells in culture (Kozlowski

~

.a.J...., 1984). Results from these types of studies clearly show in
some instances large increases in the amount of proteases on the
surface of tumor cells, a result which will be discussed further.
Because of the difficulties involved in studying samples of
ill .Y1YQ. tumors, many researchers have studied the production,

secretion, and properties of tumor produced proteases utilizing
tumor lines maintained in culture. Again, most researchers find an
increased amount of proteolytic activity associated with the tumor
cells compared to their normal controls (Sloane and Honn, 1984;
Dano~

.aJ..., 1985). And again there are studies which fail to find

a correlation, and reasons why this correlation might not be seen.
Some enzymes are secreted as zymogens and if not activated before
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the assay, their activity would not be correctly measured. Also,
some cells produce both a certain protease and an inhibitor for
that enzyme

(Roblin tl.sl.., 1978), and again, the question of the

amount of protease produced under ill yitro conditions as opposed
to the amount produced ill.v.1Y2. when the cell is actually in the
process of invasion may make measurements of this type less than
conclusive. This is especially important when it is realized that
tumor cells change their phenotype rapidly and adapt to culture
conditions, which can result in a change in metastatic ability
(Honn tl

.sl_,, 1986;

Miner t l .aJ..., 1982).

Using the same primary tumor, it has been possible to select
for sublines which vary in their metastatic ability and /or target
organ of metastasis. This has provided another model for studying
properties associated with the metastatic phenotype. The best
known group of these sublines are those developed from the B16
melanoma originally isolated by Fidler (Fidler, 1973).

By various

selection procedures, which usually include injection into
animals, collection of metastases, growth in culture, and
reinjection into animals, lines selected for high lung
colonization, increased invasion, brain metastasis, ovary
metastasis, and others have all been developed (Fidler, 1973;
Hart, 1979; Nicolson, 1982). Using these lines, different authors
have demonstrated a correlation between metastatic potential or
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invasion and many different properties, including increased PA,
cathepsin B, type IV collagenase, Factor X activating enzymes

and

beparanase activity (Wang .e.t_ .al., 1980; Sloane .e.t_ .sJ..,, 1981;
Liotta et

.al_,,

1980a; Gilbert and Gordon, 1983; Nakijima

1983). In addition, at least one study

(Nicolson~ .a.l_,,

~

.aJ...,,

1976)

showed no correlation between plasminogen activator and
metastasis, although all lines produced higher levels than normal
cells. Since PA's activate a cascade type mechanism, it may be
that only small amounts of PA are needed in order to enable a cell
to metastasize, and other factors may determine the efficiency of
the process.

2. PLASMINOGEN ACTIVATORS AND METASTASIS

In addition to the general experiments discussed above, there
exists a large body of literature dealing with the roles of
specific proteinases in metastasis. PAs are one of the most
studied of these enzymes, and several recent reviews discuss these
results in detail (Dano

~ .iill_.,

1985). There exist two distinct

types of PAs in mammalian systems, the urokinase type and the
tissue type (tPA). tPA is normally produced by endothelial cells
lining the blood vessels and is believed to be involved in
maintaining hemostasis. Urokinase type PA was originally purified
from urine, but seems to have a more general role in tissue
degradation and is produced by a number of normal cells during
tissue remodeling processes. Both enzymes are serine proteases
which act by cleaving the proenzyme plasminogen at a specific ArgVal bond to generate the serine protease plasmin, which has a
broad trypsin-like specificity. Plasminogen, which is produced by
the liver, is known to occur throughout the body in significant
quantities and can thus act as a large reserve of proteolytic
activity. Plasminogen is the only known protein substrate of PAs.
Both UK and tPA have been purified from a number of sources.
Antibodies do not cross react between the two types of enzyme, but
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antibodies against one type will cross react with the same type
enzyme from another species. The human enzymes have been cloned
and sequenced and their position on the chromosome is known
(Rajput
(Belin

~.al_.,

~.sJ...,

1985). The gene for murine UK has also been cloned
1985). Both types of enzymes have also been shown

to exist in various forms. Human UK is secreted as a one chain
protein of Mr 55,000, which although analogous to the proenzyme
form of most serine zymogens, has recently been shown to be active
against its native substrate, plasminogen (PLG) (Lijnen

~ .al_.,

1986). The one chain form is not active against small substrates,
and shows low reactivity with inhibitors. In plasma, the
activation of plasminogen by one chain UK is inhibited, and this
inhibition can be neutralized by the formation of a fibrin clot.
When cleaved by plasmin, the UK exists as a fully active 2 chain
molecule of the same Mr and also as an active, partially degraded
form of Mr 30,000. The tPA, (which has been shown by DNA
sequencing to be very different from UK), is likewise produced in
a one chain form which is reported to be partially active,
although some experiments indicate it may not be
.al_.,

(Andreasen~

1984). This enzyme has a Mr of approximately 70,000 and can

be cleaved to a more active 2 chain form by the action of plasmin.
Again, the activity of tPA towards plasminogen is increased in the
presence of fibrin, and this has important implications to the
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natural regulation of PA activity. A partially degraded form of
tPA which retains activity has also been reported (Dano

~.al..,

1985). In the human, both enzymes are glycoproteins. In the mouse,
the UK type is not glycosylated, which results in a slightly lower
Mr of approximately 48,000

(Belin~

.al.., 1985). The larger tPA

molecule contains additional peptide sequences, recently located
on the heavy chain (Rijken and Groeneveld, 1986), which are
responsible for this enzyme's high affinity for fibrin clots.
Although some tumor cells secrete increased amounts of tPA,
urokinase is the type of enzyme most usually found associated with
tumors, although in earlier studies antibodies were not always
available to distinguish between the two types. One of the
arguments that support the role of UK in the invasion and spread
of cancer is the fact that UK is often produced by cells
undergoing normal processes of invasion and tissue destruction.
Thus in the involution of mammary glands after the cessation of
lactation, Ossowski

~.al..

(1979) showed a good correlation

between an increase in UK PA in the mammary gland tissue and the
process of involution. This was demonstrated temporally by varying
the time at which the litters were removed and also by using
hormone combinations which affected the beginning of involution
and UK PA production in the same manner. It has been suggested
that the process of involution is very similar to the invasion of
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neoplastic cells, as in both processes a substantial amount of
tissue destruction takes place, including the degradation of
basement membrane structures. Evidence of the same nature also
shows that PAs are probably involved in several stages of the
reproductive cycle, including the production of PAs by granulosa
cells and the oocytes in the process of follicle disruption, the
implantation of fertilized eggs into the uterus (trophoblast
invasion), and possibly the penetration of sperm into the egg
(Huarte

.e.t_

.al., 1985). Another example of normal cells utilizing

UK to invade comes from studies which show that stimulated
macrophages and polymorphonuclear leukocytes produce UK, whereas
the unstimulated cells do not (Werb .e,t..s.l..., 1980). Thus there
exist normal situations analogous to the invasion of a tumor cell
into normal tissue in which it appears that PAs, particularly UK,
are intimately involved. This is an important consideration in
view of the fact that this situation has not yet been shown to
exist for some of the other proteinases implicated in the process
of metastasis, with the possible exception of collagenase.
It is also significant to note that by activating
plasminogen, UK may be triggering a cascade of proteolysis, since
plasmin has been shown to activate latent collagenase (Paranjpe
.s.l_.,

1980) and possibly other proenzymes as well. Thus PAs are

well suited to their proposed role of destroying normal tissues,

~
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including basement membrane type IV collagen. In addition, plasmin
has been shown to be capable of modifying a number of normal
cellular properties by altering cell surface components. For
example, plasmin treatment can stimulate cells to divide, to
secrete various factors, or even to secrete additional proteases
(Werb and Aggeler, 1978). Plasmin has also received some interest
as an enzyme which may cleave host produced antibodies against the
tumor cell (Latner t l .aJ..., 1974).
The study which perhaps most strongly indicates that PAs are
necessary for the process of metastasis was performed by Ossowski
and Reich (1983). These experiments studied the invasion and
metastasis of human carcinoma cells grown on the chorioallantoic
membrane (CAM) of chicken embryos. In this model system, the tumor
cells invade through the CAM, penetrate into the circulation,
lodge in the lungs and develop into metastasis. The authors showed
that the carcinoma produced significant amounts of UK type PA.
Injecting the embryo with a specific inhibitory antibody against
the carcinoma UK reduced the number of metastasis drastically (in
some experiments, by 95%). Although this experiment seems to
conclusively indicate an important role for UK, it must be taken
into consideration the non-homology of the system used. A human
carcinoma growing on a chicken egg is in a significantly different
environment than a human carcinoma growing in a human. In a recent
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abstract (Ossowski and Wilson, 1986), the authors have reported
similar results with the same carcinoma line in nude mice, but
again, the immune system plays an important role in metastasis and
can not be ignored. However, the use of a specific inhibitory
antibody is a promising approach which has produced strong
evidence for the importance of UK to the process of metastasis.
In another system, these authors have shown that
hydrocortisone, which suppresses the synthesis of PA by mouse
mammary tumors in yitro, also inhibits the growth and incidence· of
these tumors ..i...n

.v.iY.Q.

(Mira-y-Lopez t l

~.,

1985). One common

criticism that this study shares with others of this nature is
that the question of whether hydrocortisone is inhibiting the
synthesis of UK and consequently inhibiting tumor growth, or if
hydrocortisone is somehow affecting the growth of the tumor and
consequently inhibiting the release of PA, is not clear.

It was

mentioned above that the production of UK by normal mammary gland
tissues is also regulated by hormones, which further complicates
this issue. In either case, it is apparent that an increase in the
production of plasminogen activator is closely correlated to the
growth of this particular tumor.
Further studies on the importance of PA to metastasis attempt
to show a coordinate modification of PA production and
tumorigenicity. In one of these, a clone of the B16 melanoma was
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shown to have a decreased ability to form tumors when grown in
culture medium containing 5-bromodeoxyuridine {Christman

~

.a.J....,

1975). It was subsequently shown that these cells also showed a
coordinate decrease in PA expression when grown in 5bromodeoxyuridine. These changes were both reversible. In
addition, a clone maintained in 5-bromodeoxyuridine which
permanently lost its tumorigenecity also produced no detectable
PA. It should be noted here that as in most studies or this type
another group reported the opposing view. Using a Syrian hamster
melanoma which only displayed transformed characteristics in the
PRESENCE of 5-bromodeoxyuridine, Rosenthal

~ ~.

(1975) report

that PA was again suppressed by 5-bromodeoxyuridine, and therefore
not associated with transformation. However, this paper did not
give any details about whether this mutant line was actually
tumorigenic. This study also illustrated that at different stages
or growth in culture, different levels of PA were produced. This
phenomena has been observed by other authors as well and may again
be a reason for discrepancies between research groups. Further
studies with the mouse melanoma line suggests that cocultivation
of nontumorigenic and tumorigenic lines results in a suppression
of PA production by the tumorigenic line

{Newcomb~

.al_.,1978).

Furthermore when this mixture of cells was innoculated into
immunocompetent mice, tumor production was suppressed; however the
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same mixture produced tumors in immunodeficient mice. This may
indicate a role of plasminogen activator-plasminogen (PA-PLG)
proteolysis in the protection of tumor cells from the immune
system • In another model system, using clones of a rat mammary
carcinoma, a strong correlation between PA activity and metastatic
potential was also observed

(Carlsen~

.sY..., 1984). In this study

there seemed to be a threshold level of PA activity, and clones
with PA levels higher than this threshold produced high numbers of
metastases.
Stronger evidence for the involvement of PAs in metastasis,
which may or may not hold up to further scrutiny by the scientific
community, comes from viral transformation studies. Some of the
earliest evidence for a role of PAs in metastasis came from work
done on viral transformation by Rifkin and Reich. They showed that
transformation of chick embryo fibroblasts by Rous sarcoma virus
(RSV) results in the production of UK (Unkeless

~

.sY,.., 1973),

which is not produced by the normal fibroblasts. This production
of UK is dependant on the development of transformation since in
cells infected with non-transforming RNA or DNA viruses, no
increase in UK is seen. Likewise when cells were infected with a
temperature sensitive mutant strain of RSV which only produced
transformation at the permissive temperature, PA production was
also increased only at the permissive temperature. PA production
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and transformation were both reversible with changes in
temperature, and the increase in PA was the earliest biochemical
event detected after transformation.

Ossowski~ .al,.

(1974) showed

that the morphological changes observed upon transformation
depended on PA-PLG activity. In addition, the tumorigenecity of
virally transformed cells in nude mice has been shown to correlate
with PA activity. Again, some authors have claimed to the contrary
that temperature sensitive variants produce tumors even at the
non-permissive temperature (Poste and Flood, 1979), and that the
production of plasminogen activator is not related to
tumorigenicity using these same strains (Wolf and Goldberg, 1978).
However closer examination shows in the case of the temperature
sensitive mutants (Poste and Flood, 1979) the production of PA was
not actually measured under the conditions of the tumor formation,
and in the second case (Wolf and Goldberg, 1978) all of the lines
which produced tumors in the absence of high PA production grew as
noninvasive tumors encapsulated in a tough fibrous coat. Thus,
although the literature shows a close correlation with PA
production and transformation, PA production may not be necessary
for tumorigenicity, depending on the system used. However, even in
cases of low PA production there seems to be a strong indication
that its action may be necessary for invasive growth of the tumor.
Similar results have been reported using other viruses and cell
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lines, and increased PA activity has also been observed in cells
transformed by chemical carcinogenesis (Dano t l

.al_.,

1985).

In other studies, the expression of PAs has been shown to be
modulated by hormones in hormone sensitive tumors (Ossowski t l

.aJ..., 1979), to be induced by damage to cellular DNA (Miskin and
Reich, 1980), and also to be stimulated by tumor promoters such as
phorbol myristate acetate. Goldfarb and Quigley (1978) have shown
that phorbol myristate acetate treatment increases the synthesis
of PA in normal cells, resulting in morphological changes, and
also increases the already high production of PA by transformed
cells. Again, this evidence only supports a correlation between PA
production and transformation or tumor growth. Likewise it has
often been demonstrated that there is usually a good correlation
between production of plasminogen activators and other of the
transformation phenotypes studied in culture, such as anchorage
independent growth, reduced cellular adhesiveness, and increased
cell migration (Quigley, 1979b).
Another model system which has been used to study the role of
proteinases in invasion and metastasis developed by Liotta uses a
human amnion membrane to quantitate tumor cell invasion through a
basement membrane (Liotta tl.sl..., 1980b). Although in most studies
using this system, collagenase is the only proteinase shown to
correlate with invasion, recent evidence indicates UK may also be

24
important. Rifkin (1986) reports that anti-UK (but not anti-tPA)
antibodies prevented invasion of the amnion by B16 cells. An
important consideration in interpreting these results is of course
the lack of many i..n.YiY.2. factors, and the fact that most
investigators perform these studies under slightly different
conditions.

3. CATHEPSIN B AND METASTASIS

Although the evidence for an important role of cathepsin B in
metastasis is not as extensive as that for PAs, research in this
area indicates that cathepsin B is important in at least some of
the tumor systems studied (Sloane

~.ill..,

1986). Cathepsin B is a

cysteine protease with a Mr of approximately 25,000 and a broad
endopeptidase activity. Normally found in the lysosomes, cathepsin
B has a major function in the degradation of proteins.

Cathepsin

B has an acidic pH optimum of around 6, and is subject to rapid,
irreversible denaturation above pH 7. Lysosomal proteinases in
general may be increased in metastasis, and the possible existence
of "extracellular lysosomes" may be significant in this respect.
However, very little evidence exists on this subject. Original
work in this field was dedicated to confirming that the existence
of cathepsin B activity within tumors was a property of viable
tumor cells, and not just an artifact from tumor cell necrosis or
invasion of normal phagocytotic cells. Also, there were
difficulties with explaining how a protease, usually intracellular
and inactive at neutral pH could be involved in extracellular
destruction. Thus it is significant that a cathepsin B-like
protease with slightly different properties than the normal
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protease has been described (Sloane

iU_

.aJ..., 1984, Mort

iU_ Al_.,

1980). This enzyme has increased stability at higher (above
neutral) pH and appears to be localized in the plasma membranes,
as well as the lysosomes, and perhaps exists in a shed or secreted
form. The enzyme is often found in a latent form which can be
activated by pepsin treatment and/or a higher Mr form
(approximately 40,000). The enzyme is immunologically cross
reactive with cathepsin B under appropriate conditions, and so is
described as a pro-cathepsin B or cathepsin B-like enzyme.
Cathepsin B is capable of degrading the non-helical portions of
collagen, fibronectin, proteoglycans and can also activate latent
collagenases and therefore, like PA, is capable of initiating a
proteolytic cascade. Increased secretion of a cathepsin B-like
protease would therefore enable a tumor cell to degrade most
extracellular structures that a migrating tumor cell may
encounter. There is also evidence that cathepsin B localized in
membranes may be resistant to plasma protease inhibitors (Sloane
and Honn, 1984). Because of these properties, it is reasonable to
propose that extracellular cathepsin B may play a role in the
invasion of tumors, even in an environment (high pH, proteinase
inhibitors) where lysosomal cathepsin B would not be active.
Similarly to PA, there is accumulating evidence that
cathepsin B may be involved in non-neoplastic tissue destruction.
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Early evidence correlated higher levels of cathepsin B activity in
tissue remodeling and inflammation (Nakagawa
and Ali, 1978; Davies

~.al,..,

~.ill_.,

1977; Bayliss

1978). However, these studies did

not distinguish between intra- or extra- cellularly located
cathepsin B and therefore may simply represent an increase in
lysosomal activity in these conditions. Recently, Recklies and
Mort (1985) have demonstrated in culture medium from lactating
mammary gland explants the existence of stable, active, high
molecular weight forms of both cathepsin B and L. These authors
propose that the secreted immunologically related precursor forms
may represent an abnormal form which is incompletely processed. It
is interesting to note that these authors found hydrocortisone
inhibited the release of the cathepsin B-like enzyme from normal
mammary gland explants in culture (Recklies
the same way that Ossowski

~.al.

~.sJ...,

1985) in much

(1979) showed for PA. This

illustrates that the practice of studying only one of the various
proteases involved in the complicated process of metastasis may
lead to incorrect conclusions. Further support for a normal
physiological extracellular role of cathepsin B or a cathepsin Blike protease comes from a paper by Gordon

~.sJ...

(1985) which

demonstrates, in cultures of a human hepatoma line, that a Mr
54,000 protease immunologically and enzymatically related to
cathepsin B may be responsible for the the removal of a prosegment
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from proapo-lipoprotein-A-II. This indicates that a "procathepsin
B-like" proteinase can accurately process natural protein
substrates, and may function

extracellularly in normal cells.

As mentioned above, several studies have correlated an
increase in the amount of cathepsin B with tumor homogenates as
compared to homogenates of normal tissues. Histochemical studies
by Sylven

~.al..

(1974) have shown the presence of cathepsin B-

like material on the surface of a variety of tumor cells using an
immunological technique.

Poole~ .al_.

(1978) have demonstrated

that the invading edges of breast tumors have a higher cathepsin B
activity than the center of the malignancy. This localization
would be expected if cathepsin B were playing an essential role in
tumor invasion, but it does not provide causal evidence.
Increased cathepsin B has also been correlated with increased
spontaneous metastasis and lung colonization in selected sublines
of the B16 melanoma and murine Lewis Lung carcinoma (Sloane and
Honn, 1984). There also exist reports in which this correlation
failed to be demonstrated (Sloane and Honn, 1984), possibly
because of similar problems in measuring the amount of cathepsin B
in

~ ~

homogenates, or in variations induced by growing the

cells in culture in order to assay cathepsin B levels.
It has also been reported that agents which modify the
metastatic potential of cell lines concomitantly affect cathepsin

29
B activity. Takenaga (1984) demonstrated that dimethyl sulfoxide
(DMSO) increases the ability of Lewis Lung carcinoma to form
experimental metastasis and also increases the amount of cathepsin
B activity. However, treatment of this clone with DMSO also
resulted in increased activities of other proteases, including
plasminogen activator. Likewise a group of murine
methylcholanthrene-induced fibrosarcomas had elevated cathepsin B
activity compared to normal muscle (McLaughlin

~.aJ...,

1983). The

levels of cathepsin B activity did not correlate with metastatic
potential. However, the authors point out that increased
proteolytic activity may be important to some aspect(s) of
metastasis, and still not correlate with the overall process.
In experiments using the amnion membrane model in
collaboration with Dr. Persky (Persky

~.al..,

1986), it was shown

that a strong inhibitor of cathepsin B had no effect on invasion
and migration through the basement membrane. This result is in
agreement with that of other researchers using this model (Rifkin,
1986). This lack of an inhibition of invasion suggests that
cathepsin B may not be involved. Alternatively, an effect may not
be detected because of other reasons. For example, the location of
cathepsin B in this system may be unavailable to small inhibitors
of the type used (leupeptin), the cathepsin B activity may only be
required for tumor invasion

.i.n.~,

or the "pro" form of the
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enzyme secreted may be resistant to the inhibitor used.
In summary, although the number of experiments which support
an important extracellular role of cathepsin B in tissue
destruction by tumor cells is not as large as that for PA, the
experiments follow the same type of methodology and generally
support the involvement of cathepsin B in metastasis. Further
research to clarify the role of this enzyme is therefore of
significant interest.

4.THROMBIN AND METASTASIS

Thrombin is another protease which is believed to be involved
in the process of metastasis and host responses to tumors. The
role of thrombin in hemostasis is becoming increasingly more
complex, and the role which this enzyme may play in metastasis is
at present unclear. Thrombin is a 34,000 dalton serine protease
responsible for cleaving fibrinogen to fibrin at a single arg-gly
bond, which results in the initiation of clot formation (Stryer,
1981). Thrombin is produced from inactive 66,000 dalton
prothrombin by the action of another serine protease of the
coagulation cascade, Factor Xa. Factor X can be activated by
either the intrinsic or extrinsic pathway and so this is the first
common step of the two pathways leading to coagulation. Unlike PA
and cathepsin B, thrombin is not a tumor produced protease, but
many cancer patients have coagulation disorders and many tumors
have been shown to directly cause the activation of the
coagulation cascade (Rickles and Edwards, 1983). Other properties
of thrombin which may or may not be important to the metastatic
process include evidence that (1) thrombin can stimulate the
synthesis and secretion of a collagenase inhibitor from platelets
and a PA inhibitor from platelets and endothelial cells (Cooper
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1985; Gelehrter and Sznycer-Laszuk, 1986), (2) thrombin

initiates cell proliferation (Carney

~.al.,

1985), (3) thrombin

bound to thrombomodulin can activate protein C, which will result
in increased fibrinolytic activity by degrading an inhibitor of
PAs (Maruyama and Majerus, 1985), (4), thrombin can release
proteoglycans from endothelial cells, and (5), thrombin can
stimulate endothelial cells to secrete prostacyclins and tPA to
again stimulate fibrinolysis (Shimada and Ozawa, 1985).
In metastasis, thrombin is proposed to increase the
percentage of tumor cells released which survive transport in the
circulation and attach to grow into secondary tumors (Markus,
1984). By forming a fibrin clot around the tumor cells, thrombin
can lead to the aggregation of platelets and other blood
components. This fibrin/platelet covering can protect the
circulating tumor cell from the host immune system by masking the
cell surface antigens. The larger embolus is also believed to be
more easily anchored and the tumor cell can than extravasate from
this stationary phase and continue to grow into a secondary tumor.
It should be noted that the postulated role for thrombin and
fibrin formation is in direct opposition to the postulated role of
PAs. However, the possibility that tumor cells may display
different phenotypes at different stages in the metastatic process
must again be considered. Thus in the primary tumor, which is
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being surrounded by a fibrin clot and in general is under
increasing pressure to invade and expand, a high
fibrinolytic/degradative activity may be favored. Once released
into the circulation, where tumor cells do not survive very long,
the formation of a protective fibrin clot/platelet embolus may be
favored. After attachment, the degradative processes may again be
the pathway leading to successful metastasis. The action of
thrombin can, by this hypothesis, promote or retard the formation
of metastasis, depending on the local stage of the process. These
opposing pathways may also be responsible for some of the
contradictory experimental results.
Evidence for the role of fibrin function in the primary tumor
is limited at this time. Histological studies however have
generally revealed a fibrin structure surrounding primary tumors,
and when looking at a malignant tumor, places of local dissolution
or absence of this structure, as well as the basement membrane,
are apparent. In addition, studies such as the one by Colucci

~

.Ql.. (1981) give support to the theory that under these conditions,

the fibrin observed is an impediment to tumor migration and
metastasis. In their studies, different sublines of a murine
sarcoma of varying spontaneous metastatic potential were shown to
display an inverse correlation between ability to metastasize and
ability to activate coagulation of plasma. This activation was
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proposed to be due to a tissue factor, and the authors concluded
that the fibrin acts as a barrier to the primary tumor. Other
tumors have been shown to produce a tissue factor; however several
of these studies used tumor extracts which may have contained host
derived tissue factor. For example, macrophages have been shown to
express increased tissue factor activity when stimulated by the
presence of cancer, and the fibrin formed may affect macrophage
migration. Studies which attempt to correlate the amount of tissue
factor with metastatic potential may therefore not actually be
measuring tumor tissue factor.
In an interesting series of experiments,

Tanaka~~.

(1982)

tested the effects of tranexamic acid and UK injections on the
spontaneous and experimental metastasis of several tumor lines.
When rabbits received i.v. injections of V2 carcinoma cells,
treatment with UK reduced the number of pulmonary metastases. When
rabbits with primary V2 footpad tumors received i.v. UK, the
number of lymph node metastases was increased. In further studies
using the Lewis Lung carcinoma, these authors again reported an
increase in lung metastases from a primary footpad tumor when the
animal was treated with UK, but also reported a decrease in lung
metastases when the animals received tranexamic acid, an inhibitor
of the plasminogen to plasmin conversion. Thus there is strong
evidence for the proposal of conflicting roles for fibrin, and
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therefore thrombin, in metastasis; a suggested inhibitory role of
fibrin in the early stages and an enhancing role of fibrin in the
later stages. It is interesting that in experiments using a
spontaneous model, injection of UK did not prevent tumor cells
from lodging in the lungs in larger numbers, but inhibition of
fibrinolysis did prevent them from escaping the primary tumor.
This would suggest that the local degradation of surrounding
fibrin may be more important to the process of metastasis then
that of fibrin formation and attachment.

It may be that

attachment is controlled by other factors, such as damage to the
endothelium and exposure of laminin

(Terranova~

.sJ..., 1982).

However, other studies (see below}, have not always supported this
hypothesis.
There are also a number of studies which utilized inhibitors
of coagulation such as heparin or warfarin, or perhaps more
drastic measures such as infusion of plasmin or defibrinogenation
of the animal, to attempt to determine the role of thrombin and
fibrin formation in metastasis. Because of the many possible side
effects of these treatments, results from these experiments will
only be summarized here. In general, treatment with an inhibitor
of thrombin (or in some cases, inhibitors of platelet aggregation
(Honn~

.sJ..., 1986) reduce the number of metastasis. These studies

are usually most convincing when performed on i.v. injected cells.
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In spontaneous models, the results are less clear, and often
questionable because the drug used has other effects on the
primary tumor besides the inhibition of thrombin (Markus, 1984).
For example, heparin has been shown to be antimitotic, to
facilitate immune responses

(Gorelik~~'

1984), and to have

profound influences on angiogenesis (Folkman, 1985;
~'

Folkman~

1983). Warfarin inhibits the synthesis of many proteins and

by decreasing the formation of

-carboxyglutamate may have

pleotropic effects (Hilgard, 1977).
Recently a number of tumors and tumor lines have been shown
to produce a cysteine protease which is capable of directly
activating Factor Xa (Gordon and Cross, 1981; Falanga and Gordon,
1985). This activity has been purified from extracts of the V2
carcinoma, and similar factors have been reported to occur in
tissue extracts of human breast, colon, kidney, vagina and lung
cancer, transformed hamster fibroblasts, Lewis Lung carcinoma, B16
murine melanoma, and Ehrlich ascites JW sarcoma cells. This cancer
"procoagulant" has not been found in extracts of normal

tissue.

Using murine B16 melanoma and Lewis Lung tumor cells, Tohgo

~~

(1985) have shown the importance of this procoagulant in the
probable mechanism for platelet aggregation. And in several
examples, including selected sublines of the B16 melanoma (Gilbert
and Gordon, 1983), platelet aggregation has been shown to
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correlate with metastasis. Further research into the occurrence
and possible function of this interesting proteinase will
certainly be forthcoming.
Evidence such as that briefly presented here demonstrates the
profound influence of the hemostatic state of the host on cancer
invasion and metastasis. It is clear that tumors or transformed
cells are capable of causing the activation of both the
coagulation and fibrinolytic pathways, perhaps at different
stages. In a study by Kohga (1978) of ten rat ascites lines, the
highest incidence of metastases after i.v. injection was obtained
from the cells with both the highest fibrinolytic and
thromboplastic activities. Before it is possible to clinically
interfere in these processes, it is also clear that much more
research on the actual mechanism of cancer metastasis needs to be
done in order to identify the crucial steps or times for
intervention.

5. PREVIOUS INHIBITOR STUDIES

One of the most exciting prospects of research on the
mechanism of tumor cell metastasis is the hope that an increased
understanding will lead to treatment modalities which may prevent
this process. Based on the evidence currently available,
researchers have attempted to reduce metastasis through the use of
protease inhibitors. Demonstration of a clear reduction of
metastasis by inhibition of a particular protease would also
provide conclusive proof that the enzyme was participating and
further our understanding of the metastatic process.
Alternatively, lack of an effect would indicate that the protease
was not essential to the overall process. Experiments performed to
determine if protease inhibitors do have antimetastatic effects
have yielded mixed results. Because of the complex nature of
metastasis and the possible interplay of various host systems and
the many proteolytic cascades, many of these studies cannot be
clearly interpreted. Some of these have been mentioned already,
additional examples are discussed below.
Although .1.n. yitro experiments may have limited relevance to
an .1.n.

Yi.v.Q.

process, they do provide valuable preliminary evidence.

Various inhibitors of proteases have been tried in all of the .in
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yitro model systems discussed, again with various degrees of
effectiveness. In collaboration with Dr. Persky (Persky

~

.s.J...,

1976), it was shown that high concentrations of urokinase and
cathepsin B inhibitors had no significant effect on the invasion
of B16 melanoma cells through an amnion basement membrane. It was,
however, possible to completely inhibit invasion by the use of
ethylenediamine tetraacetic acid (EDTA), an inhibitor of
metalloenzymes such as collagenase. Rifkin (1986) has also
reported no effect of leupeptin on the invasion of B16 cells in
this system, and a complete inhibition by EDTA. However, he was
also able to inhibit invasion using an anti-UK antibody, but not
with an anti-tPA antibody. Since leupeptin at high concentrations
inhibits UK, the use of an antibody to inhibit UK must differ in
some way. Perhaps UK is not completely inhibited by the reversible
inhibitor leupeptin, especially when the cells are bound tightly
to the amnion, or the antibody may have other effects which result
in the differences observed between the two studies. Collagenase
has also been shown to be important by the work of Thorgeirsson §!.
.al.. (1982). Quigley has also studied the effects of proteinase

inhibitors on the degradation of extracellular matrix by tumor
cells utilizing metabolically labeled subendothelial matrix
synthesized by normal chicken embryo fibroblasts (Quigley

~.s.J...,

1986). In this system, aprotinin has no effect unless plasminogen
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is present, in which case aprotinin normalizes the rate to that
observed without added plasminogen. Diisopropylfluorophosphate
(DFP), L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E64), and 1,10-phananthrolone, all show some inhibition of the
degradation, however, even with all three inhibitors present, some
degradation still occurs. This indicates that either the cells are
producing protease in a localized way in an area where they are
inaccessible to the inhibitors, or the cells are producing a
protease which is not sensitive to the inhibitors used. Pearlstein
~,al..

(1981) showed that a specific thrombin inhibitor

(dansylarginine N-(3-ethyl-1,5-pentanediyl)amide could inhibit the
action of thrombin activated by tumor cells and thereby prevent
their aggregation with platelets. DiStefano

~,al..

(1982)

demonstrated leupeptin inhibition of a membrane protease involved
in lysing of normal red blood cells by tumor cells, as did Zucker
~

.aJ... (1985) using EDTA and minocycline (inhibitors of

metalloproteinases). These experiments, as well as many others not
mentioned here, show that specific steps in metastatic processes
can be blocked by protease inhibitors, and it is reasonable to
assume that a similar situation exists

in~.

Several important factors must be taken into account when
attempting to inhibit proteases

.in~.

First, unlike in a test

tube, the inhibitors must be free of toxic effects, both to the
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host and to the tumor cells. Secondly, the inhibitors must show
specificity towards the protease of interest. This is a major
drawback of most of the studies reported so far. Many of the
components of the complement, coagulation and fibrinolysis
pathways have identical or similar primary specificity,
principally for the basic amino acids arginine and lysine. Thus an
inhibitor like leupeptin is effective against more than one of the
enzymes postulated to be involved in metastasis. Leupeptin is a
potent inhibitor of cathepsin, but at higher concentrations it can
also inhibit many other enzymes (for further discussion see
results).
An interesting report by Gasic

~.al..

(1983) used an extract

of leech salivary gland to inhibit lung colonization by Sarcoma
T241 cells. The extract was shown to contain anticoagulation and
antiproteinase activities, however other anticoagulants (heparin
or atroxin) did not result in a significant inhibition of
colonization. Thus these authors conclude the antiproteinase
activity of the extract is responsible for the inhibition of
experimental metastasis, however, the proteases involved cannot be
identified.
Leukocyte neutral protease inhibitor (LNPI), shown to inhibit
collagenase, elastase and chymotrypsin-like neutral protease, was
reported to significantly inhibit the spontaneous metastasis of
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Lewis lung carcinoma (Giraldi

~.al.,

1977a). Further studies are

needed to identify the enzyme(s) inhibited in this system. Giraldi
~.al..

(1977b) also reported an inhibition of metastases formation

from Lewis lung carcinoma transplants by treating animals with
derivatives of N-diazoacetyl-glycine. This compound is an
irreversible inhibitor of some proteolytic enzymes, but no
experiments to identify the enzymes inhibited were reported.
Turner and Weiss (1981) in a very detailed study of Lewis
Lung carcinoma, showed aprotinin increased both spontaneous and
experimental metastasis. Aprotinin is a broad spectrum protease
inhibitor capable of inhibiting trypsin, plasmin, and also
kallikreins. They also showed treatment with aprotinin after i.v.
injection of tumor cells increased the retention of the tumor
cells in the lungs and liver. This was suggested to be a result of
inhibiting plasmin, which would allow a larger number of tumor
cells to remain attached to the endothelium by a fibrin clot. A
larger number of stably arrested cells would then give rise to a
greater number of metastases. In contrast, Latner

~ ~.

(1974)

reported aprotinin inhibited tumor growth and metastasis of a
malignant fibrosarcoma. Also, Giraldi

~~.

(1977c) reported a

significant inhibition of spontaneous metastasis of the Lewis Lung
carcinoma following i.p. injection of aprotinin. Administration of
leupeptin and pepstatin by the same protocol showed no effect,
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which suggested the lack of an essential role of cathepsins B and
D. Leupeptin, pepstatin, and antipain, also had no inhibitory
effect on the spontaneous metastsis of hamster cells transformed
by Human Herpes Simplex virus (Harvey

~.sJ...,

1977). Leupeptin was

effective, however, in reducing by fifty percent the number of
experimental metastasis of a hepatoma cell line in rats in
experiments by Saito

~.aL

(1980). In the same system,

chymostatin and elastatinal had no inhibitory effect. The authors
suggest that the reduction by leupeptin is due to an inhibition-of
thrombokinase (Factor Xa), and histological examination of the
lungs of animals treated with leupeptin prior to injection of
tumor cells showed significantly fewer tumor cell thrombi.
However, leupeptin inhibits cathepsin B 1000-fold more effectively
than Factor Xa, and at the levels used in these experiments,
leupeptin may be inhibiting other enzymes as well (see results and
discussion). Therefore the mechanism of action of leupeptin in
this system is unclear. It is again clear that protease inhibitors
have produced different results, sometimes in seemingly identical
systems. This may be due to differences in methods (i.e., Giraldi
~

.aJ.... (1977c) used 200,000 KIU of aprotinin, compared to 5000 KIU

used by Turner and Weiss (1981)), animal or tumor variations, and
may depend on the stage of metastasis being examined. It may also
be a consequence of the fact that the concentrations of the
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inhibitors used have not been carefully monitored. It has been
shown that proteinase inhibitors can be removed from circulation
rapidly (Tanaka, 1983), and also that administration of some
inhibitors may cause a compensatory overproduction of certain
enzymes (Sutherland and Greenbaum, 1983; Aoyagi et .sJJ...., 1983;
Tanaka~

.siJ....., 1984). Thus the time of the inhibitor injection may

be extremely important in terms of the proteolytic status of the
experimental animal.
A different approach to studying protease production and
metastasis has been used by Giraldi

~

s.J.... (1985a,b). In these

experiments, animals bearing different tumors of varying
metastatic potential were treated with proven cytotoxic or
antimetastatic drugs. The levels of proteases (surface neutral
protease, PA, cathepsin B) were assayed in the tumor before and
after treatment. These experiments demonstrated no correlation
between protease levels and metastases formation, nor did they
reveal any correlation between inhibition of metastasis and
inhibition of protease activity. These experiments do not directly
test the role of proteases in metastasis.
Recently nafazatrom, an antithrombotic compound (Bayer 6575)
which was shown previously to be antimetastatic (Honn

~,al.,

1982), was shown to interfere with the degradation of endothelial
matrix by B16 amelanotic melanoma (B16a) cells (Maniglia

~

.siJ.....,
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1986) • These experiments did not identify the enzymes responsible
for degradation of the matrix. In addition, Maniglia

~.s.J...

report

that nafazatrom had no inhibitory effect on the ability of i.v.
injected B16a cells to form lung colonies, indicating that the
effect of nafazatrom on spontaneous metastasis was not due to its'
antithrombotic properties. These results illustrate the difficulty
involved in studying the complex process of metastasis.

6. INHIBITORS USED IN THIS WORK

Leupeptin, acetyl-Leu-Leu-Arginine-aldehyde, is often used as
a general protease inhibitor in studies on metastasis. It has been
shown to be nontoxic and has been shown to have potent

J...n~

effects which correlate with its antiproteinase activity. For
example, leupeptin has been used experimentally to treat
pancreatitis (Jones

~.SlJ...,

1982), and 12 mg/kg three times a

week was effective at preventing the onset of muscular dystrophy
in a mouse model

(Sher~

.SlJ..., 1981). Leupeptin is a tripeptide

aldehyde in which the normally C-terminal carboxylic acid is
converted to an aldehydic function (for structure, see Appendix
A). This compound is a potent inhibitor of both serine and
cysteine proteases with a primary specificity for arginine or
lysine. The mechanism of inhibition by tri-peptide aldehydes has
been shown to occur by a transition state analog process in which
the active site nucleophile

cs-

or

o-)

forms a covalent bond with

the aldehydic carbon (Kennedy and Schultz, 1979; Frankfater and
Kuppy, 1981). This intermediate is partially stabilized by the
forces which normally stabilize the proposed transition state, but
cannot be cleaved to yield products because of the aldehyde
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substitution. It can, however, dissociate to starting materials,
so these tripeptide aldehydes are not irreversible inhibitors. It
has also been shown that, even among proteases of identical
primary specificity, altering the secondary or tertiary binding
residues can have profound effects on the affinity of a protease
for a particular tripeptide. For example, Bajuz

~.al_.

(1978) have

shown that compounds of the structure Phe-Pro-Arg have very high
binding constants to thrombin, and as mentioned above, leupeptin
has an extremely high affinity for cathepsin B. Studies on
chloromethylketones demonstrated that sequences of the formula
Glu-Gly-Arg were very effective at inhibiting UK (Coleman
1979). However, chloromethylketones are toxic in..l!i.l!:.Q..
~.

~.al_.,

Patel~

(1983) have demonstrated by synthesizing various tripeptide

aldehyde affinity resins that these peptides are capable of
selectively binding a specific enzyme based on secondary
specificity. Likewise, Kabi manufactures a series of tripeptide pnitroanilide substrates for many blood enzymes with a primary
specificity for arginine which exhibit selectivity based on the
other two residues chosen. Because of these features, i.e. low
toxicity, high specificity, and potency as inhibitors, it may be
possible to use these tripeptide aldehyde inhibitors in a model
for metastasis to distinguish the roles of proteases implicated in
metastasis.
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Another inhibitor which was used in these studies, Ep453, was
developed by Hanada

~

.slJ... (1983). A derivative of E-64, Ep453 is

a peptide epoxide (for structure, see Appendix A) which is an
irreversible inhibitor of cysteine proteases such as cathepsins B
and L, and may also be used .1.nxiY.Q. to evaluate the roles of
cysteine proteases in metastasis.

MATERIALS AND METHODS

MATERIALS
Common chemicals and reagents were purchased from Sigma (St.
Louis, MO) or Scientific Products (McGaw Park, Il). Leupeptin
(acetyl-Leu-Leu-Argininal) was a gift of Dr. W. Troll (New York
University Medical Center) or was purchased from Sigma
(synthetic). D-Phe-Pro-Argininal, t-boc-D-Phe-Pro-Argininal, tboc-Glu-Gly-Argininal, and Glu-Gly-Argininal (trifluoroacetate
salt) were all synthesized by members of Dr. R.M. Schultz's
research group. Derivatives of E-64 (L-trans-epoxysuccinylleucylamido(4-guanidino)butane) were a gift of Dr. W. Tanaka
(Institute of Microbial Chemistry, Tokyo, Japan). Kabi substrates
S-2251 (H-D-Val-Leu-Lysine-p-nitroanilide), S-2444 (pyro-Glu-GlyArginine-p-nitoanilide), and S-2238 (H-D-Phe-Pipecolyl-Arginine-pnitroanilide), were purchased from Helena laboratories (Beaumont,
TX). Human urokinase (Abbokinase, UK) was purchased from Abbott
laboratories, (North Chicago, Il) and recombinant human tissuetype plasminogen activator (rtPA) was a gift of Genetech (San
Francisco, CA). Reagents for polyacrylamide gel electrophoresis
were from Bio-Rad (Richmond, CA). Triton X-100 was from Kodak
(Rochester, NY). All cell culture reagents were from Gibco (Grand
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Island, NY) unless otherwise noted. Tissue culture flasks were
from Corning Glass Works (Corning, NY) or Falcon (Oxnard, CA).
Filter units were from Nalgene (Rochester, NY) and Millipore
(Bedford, MA). Female C57BL/6 mice 6-8 weeks of age were purchased
from Harlan Industries (Indianapolis, IN), Cumberland View Farms
(Clinton, TN) or Charles River (Wilmington, MA) depending on
availability. Animals were maintained by the Loyola University
Medical Center Animal Research Facility under fully accredited
(American Association for Accreditation of Laboratory Animal
Care) conditions with unlimited food and water.
~

CULTURE
B16-F10 murine melanoma cells, obtained from the Frederick

Cancer Center (Frederick, MD), were used for all experiments. This
subline of the spontaneously arising B16 melanoma was derived by
ten successive in Yi.Y.Q. cycles of i.v. injection into a lateral
tail vein, isolation of tumor nodules growing in the lungs, growth
in culture, and reinjection into animals (Fidler, 1973). Cells
were cultured as adherant monolayers in Dulbecco's Modified Eagles
Medium (DMEM) containing 10% fetal calf serum (FCS) and 100 U
penicillin-100 mcg streptomycin per ml (complete media). Cultures
were grown in humidified 5% co2- 95% air at 37° C in a Forma
Scientific (Marietta, OH) water-jacketed incubator. All cell
culture solutions were sterilized by filtration. Under these
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conditions, the observed doubling time was about 16 hr, which
agrees with published values (Fidler, 1975). Cells were routinely
passaged when confluent using 0.25% trypsin (crude, porcine
pancreas, Sigma) and 1mM ethylenediamine tetraacetic acid (EDTA)
in phosphate buffered saline (PBS) (2 ml for one minute). Cultures
usually contained about 10 million cells at this time and were
split 1:30. Cells were cultured in 75 cm 2 flasks in 10 ml of
complete media.
~COUNTING

AND TRYPAN

.lil&E.~ EXCLUSION~

lQB.

~

VIABILITY
Cells were counted using an improved Neubauer hemacytometer
(C. A. Hausser and Son, Philadelphia, PA). Cells were suspended in
PBS and diluted to an appropriate concentration (approximately 1 x
105). One drop of the cell suspension was placed in each chamber
of the hemacytometer and the individual cells were counted with an
Olympus (Tokyo) light microscope under a magnification of 100X.
The number of cells in the original solution was calculated by
multiplying the average of at least two determinations by the
appropriate dilution factors.
When making a determination of cell viability by the trypan
blue dye exclusion test (Phillips, 1973), 1 ml of the cell
suspension was mixed with 0.1 ml of a 0.4% trypan blue solution
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and dispersed with a Pasteur pipette 10 times. A drop of this
mixture was placed in the hemacytometer chamber. After 4 min the
number of stained and unstained (viable) cells were counted, and
the percentage viability determined. A minimum of one hundred
cells were counted to determine viability.
CRYOPRESERVATIQN .Qf. CELLS
Semiconfluent cultures of B16-F10 cells were used to prepare
frozen samples for storage. Flasks containing 2-6 x 106 cells were
harvested using a 0.25% trypsin and 1mM EDTA in PBS wash for 1
min, followed by addition of 5 ml complete media to inactivate the
trypsin. Cells were collected by centrifugation (!EC clinical
tabletop) at 2500 x g for 3 min in sterile 15 ml polystyrene tubes
(Corning Glass Works, Corning, NY). The cell pellet was then
resuspended by gentle pipetting in 1 ml freezing media (DMEM
containing 20 % FCS and 10% dimethylsulfoxide at o° C) and
pipetted into a sterile 2 ml cryotube (Nuno, Vangard Int., Inc.,
Neptune, NJ).

The cryotube was sealed, wrapped in paper towels,

placed inside a styrofoam container and placed into a -20° C
freezer for 12-16 hr. The container was then placed into a -80° C
freezer for an additional 12-16 hr. Following this slow freezing
procedure, the cryotubes were placed into a liquid nitrogen
storage tank. Several flasks of cells were frozen at the same
time, and after at least three days, one or more of the frozen
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samples were thawed and tested for viability. This was done by
thawing the frozen cryotube rapidly by immersion in a 37° C
waterbath for several min. The cell suspension was then mixed with
5 ml of complete media warmed to 37° Cina 15 ml tube and
centrifuged as above. This procedure removes excess DMSO. The cell
pellet is then resuspended in several ml of complete media and
added to a flask containing 10 ml complete media. This procedure
always resulted in a confluent culture of cells in two days or
less, indicating that the frozen cells were highly viable. Because
there are reports that B16 melanoma cells are phenotypically
unstable, after periods of 1-5 months, all growing cultures were
discarded and a sample of frozen cells was removed from storage
and used to initiate new cultures.
EXPERIMENTAL METASTASES
The effect of the protease inhibitors on metastases was
assesed utilizing the B16 melanoma model for experimental
metastasis as described by Fidler (1978) and outlined below.
Briefly, 2-3 x105 B16-F10 cells were seeded in 10 ml of
complete media. After three days, the semi-confluent cells were
collected by a mild trypsinization, washed in complete media,
resuspended in PBS, counted and diluted to 500,000 cells/ml.
Originally the cells were kept at room temperature; in later
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experiments the cells were placed in a sterile septum tube and
kept on ice to improve viability. Cells treated in this way were
always greater than 85% viable by the trypan blue exclusion
method, and were often used to initiate cultures AFTER all the
mice had been injected with no apparent decrease in viability.
Female C57BL6 mice 6-8 weeks old were obtained from Harlan,
Cumberland View Farms, or Charles River. For tumor cell
innoculation, the mice were placed (in their cages with access to
water) under a 150 watt light bulb until their tail veins were
clearly dilated (approximately 15 minutes). Individual animals
were removed alternately from the control and treated group and
gently placed in a small dish-washing basket with their tails
drawn through an opening in the side of the cage. This insured
that each group of animals received injections of cells which had
been in suspension for equal time. The tail was swabbed with 70%
ethanol in water, straightened across a cork the same height as
the tail, and 0.2 ml of the cell solution (containing 100,000 or
500,000 cells per ml) was injected slowly into the lateral tail
vein. A 0.25 ml glass syringe was used for the injections with a
clean 27 gauge 0.5 inch needle used for each animal. An injection
was considered successful when there was no resistance to the
injection. Any animals which showed blebbing of the skin or
struggled excessively were eliminated from the study. The number
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of animals successfully injected varied between experiments, but
averaged about 70%. The cell suspension was inverted repeatedly
during the experiment, and microscopic examination or the cell
suspension after the conclusion of the injections revealed no cell
clumping. Animals were sacrificed after 15 or 21 days, the lungs
were removed, rinsed in PBS, dissected into lobes, and the tumor
colonies were counted under a 30X binocular dissecting scope. Only
surface colonies were counted on both sides of the lung lobes.
Because of the presence of melanin, the black melanoma colonies
were easily distinguishable. When amelanotic colonies were
present, lungs were dissected as above and stained overnight with
Bouins solution (250 ml formalin, 750 ml saturated picric acid, 5
ml glacial acetic acid) before counting. This staining procedure
colored the normal lung tissue yellow, while leaving the tumor
nodules white so that they could be counted. Electron microscopy
was performed (Dr. Persky, Loyola University Medical Center) on
amelanotic nodules and the presence of stage III pre-melanosomes
was taken as conclusive proof that the cells forming the nodules
were melanomas (see Appendix C). Results were analysed by the
Students t-test and Mann-Whitney U test (Colton, 1974). Autopsies
were routinely performed on animals from the different
experiments. Internal organs, subcutaneous sites, and popliteal
lymph nodes were grossly examined.
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TREATMENT OF m_ Hlll! PROTEASE INHIBITORS
Protease inhibitors were introduced into mice by the
following procedures in order to determine their effect on the
process of experimental metastasis. Treatment with the protease
inhibitors was always begun before injection of the tumor cells.
All protease inhibitor solutions were sterilized by filtration.
When protease inhibitors were introduced by repeated i.p.
injection, the animals received injections 12 hr apart for a total
of 13 injections. The tumor cells were injected 1 hr following the
second injection of inhibitor. Using this protocol, animals
received the following protease inhibitors and dosages in separate
experiments: leupeptin at

5, 25, 37.5, or 50 mg/kg in 0.2 ml PBS;

t-boc-D-Phe-Pro-Argininal at 12.5, 25, or 37.5 mg/kg in 0.2 ml
PBS; D-Phe-Pro-Argininal at 37.5 mg/kg in 0.2 ml 5% DMSO, 10%
ethanol, 85% PBS; Ep453 at 50 mg/kg in 0.05 ml DMSO. Animals
treated with the UK inhibitor t-boc-Glu-Gly-Argininal received 8
injections of 30 mg in 0.2 ml PBS over a 36 hr period
(approximately every 4 hr) beginning 1 hr before the tumor cell
injection. Animals treated with the UK inhibitor (tfa)Glu-GlyArgininal received 8 injections of 30 mg in 0.2 ml PBS over a 25
hr period (approximately every 3 hr) beginning 1 hr before the
tumor cell injection. In all experiments, control animals received
equal volumes of the drug vehicle by the identical schedule.
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When osmotic pumps were used to deliver the protease inhibitor
solutions, the pumps were implanted (see below) at least 12 hr
before the tumor cell injection. The solutions loaded in the pumps
in separate experiments were as follows: leupeptin, 0.1 M in PBS;
Ep453, 0.08 M in propylene glycol; D-Phe-Pro-Argininal, 0.25 M in
40% DMSO, 60% PBS. All control animals were implanted with pumps
containing the drug vehicle. The pumps contained a minimum of 200
ul of protease inhibitor solution and administered the solution to
the animals at a flow rate of 1 ul/hr.
IMPLAHTATION.Q[OSMOTIC PUMPS
When osmotic mini-diffusion pumps (Alzet, Model 2001) were
used to deliver protease inhibitor solutions, they were implanted
according to the manufacturers instructions as described below.
The mice were anesthetized with an i.p. injection of 0.2 ml
pentobarbital solution (6.5 mgs./ml PBS) and their backs were
shaved. The area was swabbed with Betadine (povidone-iodine 10%,
Purdue Frederick Co.) solution and a small incision was made
through the skin. A subcutaneous tunnel was formed using blunt
forceps, and the pump was inserted towards the animal's head. The
opening was then closed with two 9 mm wound clips. Occasionally,
when the skin was pulled tight around the pump, the wound would
reopen to the sides of the wound clips. In these cases, the animal
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was anesthetized again and the wound repaired. Pumps were removed
by reversal of these procedures after delivery of the drug was
complete. The pumps were handled with sterile gloves and none of
the mice showed any sign of infection or discomfort.
ASSAY .Q!".. PROTEASE INHIBITOR CONCENTRATIONS llf.IIYQ.
In order to determine the

.1.n.~

concentrations of the

protease inhibitors, the serum levels of the inhibitors were
measured by the following procedures.
Mice were injected i.p. with the protease inhibitor solution
to be tested and sacrificed at selected time points by co2
suffocation. Alternatively, mice were surgically implanted with
osmotic pumps and were sacrificed on days 1-5 after the
implantation. Blood samples (approximately 1 ml) were collected
immediately by cardiac puncture after surgically opening the rib
cage to expose the heart. Blood was collected using a 22 gauge
needle, allowed to clot, and centrifuged in an Eppendorf microfuge
for 15 minutes at 4° C. The serum was collected, diluted (usually
1:2 depending on the sample size) with the buffer used in the
enzyme assay, and filtered through an Amicon YM-5 membrane (5,000
Mwt. cut-off) using the Amicon Micropartition system to remove
serum protein inhibitors. The filter units were centrifuged for at
least 30 minutes in a clinical tabletop !EC centrifuge at 2500 x g
at 4°. A sample of the filtrate (usually 200 ul) was assayed for
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the presence of the injected protease inhibitor by incubating for
3 minutes with enzyme-buffer solution and then adding the
appropriate p-nitroanilide substrate. The rate of hydrolysis of
substrate was monitored at 405 nm in a Perkin-Elmer
spectrophotometer at 25° C and compared to the control rate
obtained using serum from mice treated with only the drug vehicle.
Leupeptin and Ep453 were assayed by their ability to inhibit
papain. Papain, 100 ul of 2.8 x 10-6 M which was activated by a 30
minutes incubation in an equal volume of 30 mM dithioerythritol15mM EDTA at pH 5.2, was mixed with the serum sample to be assayed
and enough 0.3 M Na citrate/phosphate buffer pH 6.2 to bring the
total volume to 1.1 ml. After addition of 30 ul of a 1 mg/ml
solution of N-benzoyl-arginine-p-nitroanilide (BAPNA), the rate of
hydrolysis was measured. For the assay of

tFA- and t-boc Glu-Gly-

Argininal compounds, the hydrolysis of 10 ul of 5 x 10- 4 M S-2444
by urokinase (1.5 I.U. UK) was observed in a total volume of 315
ul 0.1 M Tris-0.1 M NaCl pH 7.8 containing 0.1% Triton-I 100 and
the sample to be tested. The thrombin inhibitors t-boc- and H- DPhe-Pro-Argininal were assayed against thrombin (20 mU bovine
thrombin (Pentax)) in a total volume of 1.160 ml 0.2 M P04 buffer
pH 8.0 containing 50 ul 1 x 10 -3 M S-2238 and the serum sample to
be tested. Concentrations of inhibitors were estimated by
comparison to rates obtained with known amounts of inhibitor
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added.
COLLECTION .Q[ SERUM-FREE CONDITIONED MEDIUM
For studies of the secreted B16 melanoma plasminogen
activators, cells were seeded in 75cm2 or 150cm2 flasks containing
10 or 25 ml complete DMEM. When semi-confluent, the media was
removed and the cell surface was washed twice with 4-5 ml PBS,
after which the flasks were reincubated with 10 or 25 ml of the
same media without serum (serum-free medium, SFM). After 24 hours,
the serum-free conditioned medium (SFCM) was collected and the
cells were reincubated for a second 24 hour period. The SFCM was
again collected, after which these flasks were discarded.
Sometimes media was collected for a third day if the cell layer
was still attached and morphologically healthy by microscopic
examination. If the cells were heavily confluent, incubation in
SFM often resulted in sheets of cells releasing from the dish, and
this media was always discarded. Variations to try to improve the
yield and efficiency of this procedure, such as selection
procedures to develop a cell line which would be maintained in SFM
or recycling of cell cultures after a passage in SFM, and the use
of serum supplements (Ultroser G., LKB) were attempted. However,
none of these attempts proved fruitful (see Appendix B). After
collection of the SFCM, it was centrifuged at 6000 rpm and the
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supernatant was frozen at -20° C until further study. In recent
experiments, the SFM (Sigma) was supplemented with 4.5 g glucose/L
to increase the nutritional properties of the SFM and/or 30 KIU/ml
of aprotinin (Sigma) to inhibit proteolytic degradation of the
plasminogen activator.
PLASMINQGEN ACTIVATOR ASSAYS
Three separate assays were used for determining PA activity.
The first measures the ability of PA to produce zones of lysis on
a fibrin-agar substrate by activating plasminogen, and

was

performed essentially as described by Lassen (1953). Agar (Kodak)
2.5% with 0.02% NaN 3 added to inhibit microbial growth was
prepared by autoclaving and then aliquoted into sterile 15 ml
plastic tubes (Corning), capped and stored at room temperature.
Human plasminogen (Worthington) was dissolved in PBS at an initial
concentration of 10 mg/ml and then treated with DFP (Aldrich) to
inactivate plasmin. Solutions of plasminogen were incubated for at
least one hour with DFP at a final concentration of 25 mM and then
assayed using S-2251. This treatment was repeated until the
plasmin activity could no longer be detected, and the solution was
then dialysed against PBS, aliquoted into plastic tubes (5 ml
polystyrene, Sarstedt) and frozen at -20° C until use. Fibrinogen
(Bovine type IV, Sigma ) was originally further purified (Laki,
1951; Mosesson, 1962), but this was found to be unnecessary. A 10
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mg/ml fibrinogen solution in PBS containing 0.02% NaN

3 was used.
Bovine thrombin (Pentex, Miles laboratories) was dissolved in 0.9%
NaCl and frozen at -20° C in 1 ml fractions each containing 100
IU. For preparation of fibrin-agar plates, a tube of 4 ml agar was
heated in a boiling water bath until melted. This was placed in a
heated water bath at 45° C. To this tube was added 0.8 ml of PBS
with 0.02% NaN 3 or 0.8 ml of plasminogen solution also at 45° C
and 37 ul thrombin solution. The tube was inverted and then 2.5 ml
fibrinogen solution was rapidly added, the solution inverted, and
poured smoothly unto a petri dish (diSPo, sterile polystyrene, 10
x 1.5 cm, Scientific Products) which was warmed to 45° C by
floating in the water bath. The dish was placed on a level surface
and allowed to harden. For controls, it was found to be most
convienant to pour the fibrin agar plate without adding
plasminogen and then heating the plate to 80°

c for 40-50 minutes

(Lassen, 1953). This procedure denatured the contaminating
plasminogen without affecting significantly the ability of plasmin
or trypsin to degrade the fibrin. When plasminogen activators were
present in the sample, they produced active plasmin which degraded
the fibrin layer and resulted in clear zones of lysis. This test
was not used qauntitatively, but verified the presence of
plasminogen activator activity. Plates varied in their stability
but could usually be observed for 3-4 days before non-specific
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lysis from contamination appeared.
The second assay used involved measuring plasminogen
activation by measuring the rate of hydrolysis of S-2251 by the
active plasmin formed. In this assay 100 ul of plasminogen
solution was added to 1 ml of 0.05 M Tris pH 8.8 and 25 ul of S2251 (2.5 mg/ml H2 0). Absorbance was followed at 405 nm in a
Perkin Elmer specrophotometer for several minutes to observe any
backgound rate. The reaction was then repeated using a sample of
the solution to be tested for PA activity and enough buffer to
make the volumes equal, and the acceleration in rate was observed.
Alternatively, the PA sample was added directly to the mixture and
the acceleration was observed.
Finally, the urokinase-specific substrate S-2444 was used to
assay the presence of UK-like enzymes and to determine inhibition
constants. Generally, these assays involved mixing the sample (100
ul) to be tested in enough 0.05 M Tris buffer pH 8.8 to bring the
volume to 1.1 ml. Substrate was then added (25 ul of S-2444, 5 x
10-3 M) and the rate of hydrolysis was measured at 405 nm in a
Perkin-Elmer spectrophotometer (Hitachi, Ltd., Tokyo, Japan). When
using samples prepared from B16 melanoma cell cultures, this assay
was usually done in the presence of 30 KIU per ml of aprotinin to
inhibit other trypsin-like proteases which may have been present.
Aprotinin does not affect PAs at this concentration (Dano

~.al.,
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1985).
PURIFICATION .Qf.IUQ. PLASMINOGEN ACTIVATOR
The purification procedure described here was the final
procedure used to prepare samples for the experiments described,
although various modifications were attempted.
based on that of

Dano~~.

This procedure was

(1980). SFCM was thawed and adjusted

to pH 5.5 with acetic acid, made 0.1 % in Tri ton X-100, and 0.01 M
in ZnC1 2• This was applied at a flow rate of 1 ml/min to a DEAE
Sephadex-A25 (Pharmacia) column (5-7 x 2.5 cm.,Biorad) coupled to
a p-aminobenzamidine affinity resin (Pierce,

-aminocaproic acid

spacer on agarose, 5-10 x 1 cm.) in the cold.

The columns were

equilibrated with 0.01 M acetate pH 5.5, containing 0.1% Triton
X-100, 0.2 M NaCl, 0.01 M ZnC1 2• After the sample had been
applied (usually 500-1000 ml), the columns were washed with the
equilibration buffer until absorbance reached baseline or until
the red dye of the media was eluted. The columns were then
disconnected and the benzamidine column was washed with the same
buffer made 0.5 M in NaCl (until baseline reached zero or at least
10 column volumes). The bound plasminogen activators were then
eluted using 0.5 M arginine in 0.01 M acetate, 0.1% Triton X-100,
0.01 M ZnC1 2 , pH 5.5 (usually 50-100 ml). This solution was then
concentrated under N2 pressure using an Amicon PM10 filter in an
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Amicon stirred ultrafiltration device kept in an ice bath. If
necessary, buffer exchanges were performed by repeated cycles of
dilution and dialysis using the same system. Earlier variations of
this procedure were performed at room temperature or were
performed without addition of ZnC1 2 , and eluates were concentrated
by lyophilization.
IRREVERSIBLE INHIBITION

.Qf:1ll.Q.

PLASMINOGEN ACTIVATOR

For the DFP and p-chloromercuribenzoate (pCMB) inhibition
studies, 200 ul of 0.05 M Tris-.025 M EDTA pH 8.8 was mixed with
150 ul of a partially purified PA preparation. After addition of
either 30 ul DFP (135 mM in isopropanol), 30 ul isopropanol, or 30
ul pCMB (277mM in H20) these solutions were incubated for 30 min
at room temperature. 300 ul of each solution were then assayed
against S-2444, and 50 ul were assayed in the plasminogen-S-2251
coupled assay. Residual DFP was inactivated by incubation of the
enzyme sample with buffer before the plasminogen activation assay
was performed, and this was verified by showing that the
plasminogen could be activated by urokinase.
DETERMINATION

.Qf:

INHIBITION CONSTANTS

For inhibition studies of rtPA, a 0.1 mg/ml solution in 0.01
M acetate, 0.1% Triton X-100, 0.2 M NaCl, pH 5.5, was used.

To

100 ul of this solution was added the inhibitor solution and
enough 0.05 M Tris-0.2 M NaCl pH 8.8 to bring the total volume to
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1.075 ml. After a 3 minute incubation, 25 ul of S-2444 (final
concentration 1.1 x 10- 4 M) was added, the cuvettes were inverted
three times, and the rate of absorbance change was followed at 405
nm in a Gilford Response or Perkin-Elmer recording
spectrophotometer for the initial 30 minute period. All inhibitors
were tested at at least two different concentrations, and each was
performed in triplicate. Stock solutions of inhibitors were made
up as follows: tfa-Glu-Gly-Argininal, t-boc-Glu-Gly-Argininal, and
leupeptin were dissolved at 1mg/ ml in 0.05 M Tris-0.2M NaCl, pH
8.8; D-Phe-Pro-Argininal, 3. 7 mgs. in 1.875 ml Tris containing 25
ul DMSO; t-boc-D-Phe-Pro-Argininal, 2.4 mgs in 1.6 ml Tris
containing 0.6 ml DMSO; DNS-Glu-Gly-Argininal, 4.4 mgs in 1.025 ml
Tris containing 25 ul DMSO. When necessary, inhibitor solutions
were diluted in Tris buffer ( 0.5 M, pH 8.8).
Kis were calculated by the equation below where (I)
inhibitor concentration, vu
and v1

= the

= the

= the

rate in the absence of inhibitor

rate in the presence of the inhibitor. These

experiments were performed under first order conditions with
substrate

< Km.
(I)

- 1

r
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Inhibition constants against partially purified B16 melanoma
PA and concentrated SFCM were estimated in essentially the same
way, except for the partially purified preperation, the Tris
buffer contained 0.25 M EDTA to remove any remaining zn++, and the
reaction times were 60 and 100 minutes respectively, due to the
lower enzyme concentration.
POLYACRYLAMIDE

~

ELECTROPHORESIS

Discontinuous sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) was performed to determine the purity
and molecular weights of plasminogen activators in samples
prepared from the B16 melanoma by comparison to standards of known
molecular weight. The procedure was that of Laemmli (1970) as
detailed by Crowe

~.£\l...

(1978). All electrophoresis equipment and

reagents were from Bio-Rad (Richmond, CA). Gels were 16 x 18 cm x
0.75 cm thick and were composed of a stacking gel (4-5 cm) of 3%
acrylamide and a resolving gel of 11% acrylamide. Electrophoresis
was performed at 25 mA for 6 hr or at 10 mA for 14-16 hr in a
running buffer of 0.025 M Tris, 0.192 M glycine pH 8.3 containing
1% SDS. Acrylamide stock solution (30% acrylamide-0.8%
bisacrylamide in distilled water) was filtered through Whatman
(Clifton, NJ) fluted paper and stored in the dark at 4° C. The
lower gel buffer was 1.5 M Tris pH 8.8 containing 0.4% SDS and the
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stacking gel buffer was 0.5 M Tris pH 6.3 containing 0.4% SDS.
Polymerization was initiated by the addition of 75-150 ul of 10%
ammonium persulfate and 10 ul of N,N,N',N'tetramethylethylenediamine. Samples for electrophoresis were
diluted 1:1 in sample buffer (sample buffer contained: 10 ml
glycerol, 23 ml SDS (10%), 2 ml bromphenol blue (0.1%), 8.3 ml
stacking gel buffer, 6.7 ml H2o). Protein molecular weight
standards (Bio-Rad, Richmond, CA) were as follows: lysozyme,
14,400; soybean trypsin inhibitor, 21,500; carbonic anhydrase,
31,000; ovalbumin, 45,000; bovine serum albumin, 66,200;
phosphorylase B; 92,500. Gels were stained in 46% methanol, 8%
glacial acetic acid, 0.1% Coomassie Blue (500 ml). Gels were
destained in several washes (250 ml) of 20% methanol-8% glacial
acetic acid.
VISUALIZATION .Q[ PLASMINOGEN ACTIVATORS

~

ZYMQGRAPHY

When gels were overlayed on fibrin-agar plates to visualize
the position of PAs, the procedures of Granelli-Piperno and Reich
(1979) were followed as detailed by Crowe

~ .sl_.

(1978).

This

procedure consisted of running the samples on SDS-PAGE under the
usual conditions (see above), but instead of fixing and staining,
the gel was soaked in a 2.5% v/v solution (250 ml) of Triton-X 100
for at least 1 hour, with gentle agitation. This replaces the SDS
with Triton X-100 and allows the PAs to regain enzymatic activity.
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This gel is then rinsed in dH 20 and carefully overlayed on a
fibrin-agar substrate prepared in a petri dish as described above,
only in a 10cm square dish (Lab Tek) using double the amount of
solutions. The plate was then incubated at 37° C in the humidified
cell culture incubator. When plasminogen activators were present
in the electrophoresis gel, they diffused into the fibrin-agar
substrate and activated plasminogen to plasmin. The plasmin then
produced clear bands of lysis which allowed the positions of
plasminogen activators in the original electrophoresis gel to be
determined.
ANTIBODY STQDIES
Goat anti-human tPA and goat anti-human UK IgG antibodies
were purchased from American Diagnostica (batch #s 8312/0105 and
8412/12). 5 mgs of each were reconstituted in 1 ml of sterile
filtered 0.05 M Tris pH 8.8 and mixed well. Each antibody solution
(15 ul) and 15 ul of Tris were added to 15 ul of the purified PA
preparation in individual microcentrifuge tubes and vortexed.
Tubes were incubated for 3.5 hours at room temperature, and then
10 ul of each solution was spotted in wells punched on a fibrin
agar plate, in duplicate. The fibrin agar plate was then incubated
at 37° C and examined regularly over the next 5 days for signs of
lysis.
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PROTEIN DETERMINATION
Protein was determined by the method of Lowry (1951) or by
using the Pierce BCA reagent and comparing to standard curves.
When Triton X-100 was present in the Lowry assay, SDS was added at
a concentration which would prevent precipitation (Bonsall and
Hunt, 1971).

RESULTS
SELECTIVITY OF TRIPEPTIDE ALDEHYDE INHIBITORS
Peptide aldehydes have been synthesized with sequences
designed to inhibit proteolytic enzymes implicated in the
metastatic process.

The enzymes chosen for investigation in this

study were cathepsin B, thrombin, and urokinase.

The peptide

aldehydes, t-boc-D-Phe-Pro-Argininal, D-Phe-Pro-Argininal, (R-DPhe-Pro-Argininals), (tfa)Glu-Gly-Argininal, t-boc-Glu-GlyArgininal, (R-Glu-Gly-Argininals), and leupeptin, were tested for
their ability to inhibit the selected proteases believed to play a
role in metastasis.

From the determined Ki values in Table 1, it

is clear that leupeptin is an extremely potent inhibitor of
cathepsin B.

The Ki of leupeptin for cathepsin B of approximately

4 x 10-9 M indicates that leupeptin is an extremely potent
inhibitor of cathepsin B.

Likewise the Ki's of the R-D-Phe-Pro-

Argininal compounds against thrombin of 10-8 M show that these
compounds should be able to effectively inhibit the activity of
thrombin .1.n.

~

The Ki values of the R-Gly-Gly-Argininal

compounds for UK are higher than those of the thrombin and
cathepsin B inhibitors, but they are still selective for UK (see
below). By using higher concentrations they should still be
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Table 1. Inhibition constants of tripeptide aldehydes
against proteinases implicated in the metastatic process (from
Ostrowski tl .s.l..., 1986).

!nh1b1t1on Constan.t.1. 2I.. Peptidyl Aldehydes Against Selected Protease Enzyme3

'1•

Enzym~

H.

Ac-Leu-Leu-

D-Phe-Pro-

Boc-D-Phe-Pro- Glu-Gly-

Boc-Glu-Gly-

Arg1a1nal

Argininal

Argininal

Argininal

Argin1nal

Thrombin

ll. 7x10· 6

1.1:110-8

1.5x10· 8

>2x10·ll

>2x10- 4

Factor Ia

5.1x10- 6

s.2x10·5

3.9:110-6

>2x10·ll

3.1:110· 4

Urokinase

7.1:110-5

2.ox10· 11

2.2:110-6

2.1:110-5

5.4x10·5

Plasmin

1.ex10·6

2.6x1 o-5

2.6x10-6

>2:110-ll

1.6x10· 4

Cathepsin B

3.7x1o-9

>2x10-s

>2x1o-5

>2x10·5
-I

w

74
effective at inhibiting UK in an .in.Y1.Y.2. model for metastasis.
As mentioned previously, leupeptin can also inhibit other
enzymes believed to be involved in metastasis. Thus the Ki values
of leupeptin against thrombin, UK, factor Xa, and plasmin were
also determined. These are given in Table 1. The Ki value which is
closest to that of cathepsin B was obtained for plasmin (2 x 10- 6
M).

The ratio Ki plasmin I KI cathepsin B is indicative of the

specificity of leupeptin and shows that leupeptin is approximately
500-fold more effective at inhibiting cathepsin B than plasmin.·
This selectivity of leupeptin is even greater for the other
enzymes proposed to be involved in metastasis.

Likewise, D-Phe-

Pro-Argininal has a Ki plasmin I Ki thrombin of approximately 250.
The R-Glu-Gly-Argininal compounds were not as effective at
inhibiting UK and therefore their specificity ratio was about an
order of magnitude over the other proteases.

However, these

compounds still were selective for UK.
EFFECT .Qf'.. CATHEPSIN ll INHIBITORS .QN. METASTASIS
An attempt to inhibit experimental metastasis with leupeptin
was made in a manner similar to that used by Saito

~.al.

(1980).

In these experiments, leupeptin at a concentration of 50 mg/kg in
0.2 ml PBS was injected i.p. into one group of mice while the
control group received an equal volume of PBS.

Mice were injected
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with the drug solutions thirteen times, once every 12 hours.
Tumor cells, (100,000) were injected into the lateral tail vein of
each animal approximately 1-3 hrs. after the second drug
injection.

As shown in Table 2, experiment 1, the leupeptin

treated group showed a significant reduction in the number of
metastatic lung colonies (by Student's t-test).
the results of Saito

~.al.

This agrees with

(1980) who also observed a 50%

reduction in lung colonies using the same protocol with a hepatoma
cell line in rats.

However, further experiments with leupeptin

failed to yield significant inhibition (as analysed by Student's
t-test for differences about a mean and the Mann-Whitney U test).
This can be seen in Table 2 experiments 2-7.

It will be noticed

that in each case, except experiment 7, leupeptin produced a
decrease in the average number of lung colonies. (In experiment 7
the colonies had grown so large that an accurate count was
difficult.

At this time, the criteria used in counting resulted

in a minimal number, so that two or more colonies which had grown
together were counted as one, possibly resulting in the decrease
compared to the leupeptin treated group.

In future experiments,

the time before sacrifice was shortened to avoid this problem and
the maximal number of metastases were determined).

However, in

only the first experiment was this difference significant.

It is

interesting to note that in experiments 2, 3, and 5 (Table 2)

76
Table £
Effect of i.p. Injected Leupeptin on Experimental Metastasis
Number of Lung Metastases
per Animal

Mean
(±s.E.)

Control
Leupeptin (50)

13,17,21,21,37,47,51
0,7,10,15,17,18,22,31

30.±6
15±3b

2.
Control
Leupeptin ( 5)
Leupeptin ( 50)

66,68,69,88,108,180
32,38,66,72,83,125,146
26,32,36,46,69,111,168

97±18
8o±16
7o±20

Experimental
Treatmenta
1.

3.
Control

3,8,18,22,25,41,54,60,70,
73,84,92,120,133,299
4,12,14,18,28,33,47,66,70,
76,77,79,81,86,101,106,120

6o±g

4.
Control
Leupeptin (50)

1,23,33,41,54,59,121
5,6,23,44,103

47±14
35±18

5,
(20,000 cells)
Control
Leupeptin (25)

o,o,o, 1, 1, 1,9, 10, 10
0,0,0,1,1,1,1,3

3.6±1,5
o.g±o.4

6.
Control
Leupeptin ( 5)
Leupeptin (50)

1, 3, 8
0,1,2,2,5
0,1,1,5

4±1.8
2±o.8
1. 8±1. 1

Leupeptin ( 5)

74±19

7,
Control
5,6,6,14,15,20,21,36,36,41,60
Leupeptin (37,5) 0,10,18,22,28,39,40,43,44,
49,54

24.±.s
32.±.s

aNumbers in ( ) indicate mg/kg injected i.p. every 12 hours for
6·5 days. Control animals received injections of drug vehicle.
Value is significantly different from control by Student's ttest at P < 0.05.
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where different amounts of tumor cells were injected (20,000) or
lower amounts of leupeptin (5 or 25 mg/kg) were used, this trend
continued.
To verify this lack of a statistical reduction in
experimental metastasis using a strong cathepsin B inhibitor, the
peptide epoxide Ep453 was used to treat mice in the same fashion
as leupeptin.

In plasma, the Ep453 is rapidly converted to the

more soluble compound Ep475 by esterases (Hanada

~

.sJ..., 1983).

This conversion occurs in less than 30 minutes (Ostrowski

~.al..,

1986), and the Ep475 produced is a potent, irreversible inhibitor
of cathepsins and other cysteine proteases.

Again, the inhibition

of cathepsin B by this procedure produced no reduction of
metastasis as shown in Table 3.
Although this protocol has been shown to reduce metastasis in
other systems, the possibility that the dose of leupeptin used was
not sufficient to inhibit cathepsin B in this model must be
considered.

Previous data has shown that leupeptin has a short

halftime J..n..Y.1.YQ. (a halftime of 12 minutes has been reported,
Tanaka, 1983), although lower doses than that used here have had
lasting effects on dystrophy (see literature review).

In an

attempt to determine if the dosage used was sufficient to inhibit
cathepsin B, the blood levels of leupeptin were determined by the
procedure detailed in the methods section.

As shown in Table 4,
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Table 3.

Effect of i.p. Injected Ep453 on Experimental Metastasis

Experimental
Treatment a

Number of Lung Metastases
per Animal

Control
Ep453 (50)

15,31,44,46,48,54,97,113,131,139,142
8 '36, 37 '42, 42 '51 '60, 60 '80' 127' 129'
153,180

Mean
(±. S.E.)

aNumber in ( ) indicate mg/kg injected i.p. every 12 hours for
5.5 days. Control animals received injections of the drug
vehicle.
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Table

.!!.

Turnover of Leupeptin in Mouse Plasma
following i.p. Injectiona
Time {hours)

Leupeptin cone. {M)

0.5

4.9 x 10-5

1. 0

3.67 x 10-5

2.0

1.54 x 10-5

4.0

2.52 x 10-7

aMice were sacrificed at the indicated times after an i.p.
injection of 50 mg/kg of leupeptin and serum levels of the drug
were determined as described in methods.
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leupeptin is originally present at very high levels (5 x 10-5M)
following the injection.

At this level, leupeptin will inhibit

all of the proteases possibly involved in metastasis which were
targeted for study (Table 1).

After 6 hr, the level of leupeptin

was below the limit of detection in this assay, but may have still
been present in amounts capable of inhibiting cathepsin B.
Although the evidence still argues strongly against a role of
cathepsin B, an alternative method of drug delivery was used to
further test this hypothesis.
In the following experiments (Table 5), leupeptin was
delivered by continuous infusion using Alzet mini-osmotic pumps.
The pumps were loaded with an amount of leupeptin equivalent to
that delivered by injections, and the determination of the blood
level of leupeptin showed a steady level of 3 x 10-6M for at least
5 days.

In the first experiment (Table 5) only a small number of

animals were tested, and although the variation is quite large,
there was no significant reduction of metastases in the leupeptin
group.

This experiment was repeated twice using larger groups of

animals (Table 5, experiments 2 and 3). Again no significant
difference in the number of metastases was observed between the
control and the leupeptin treated animals.
The peptide epoxide (Ep453) was also infused continuously by
osmotic pump to see the effect of a second potent inhibitor of
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Table .5..
Effect of Continuously Infused Leupeptin On Experimental
Metastasis
Solution
Infused a

Number of Lung Metastases
per Animal

Mean
(± S.E.)

1•

Control (PBS)
Leupeptin
( 0. 1 M in PBS)

43,47,>300,>300
7, 15,29,222

2.

Control (PBS)
Leupeptin
( 0 • 1 M in PBS)
3,
Control (PBS)
Leupeptin
( 0. 1 M in PBS)

34,46,64,71,80,96,111,132,
133,153,157,236
74,91,102,109,109,121,127,
137,155,250

1og±16

1,2,2,3,4,4,5,6,7,7,7,7,8,8,10
0,0,1,2,2,3,4,6,20

------------------------·---- - - - --- --

asolution in () infused into animal from Alzet mini-osmotic pumps
surgically implanted into mice. Rates of infusion were 1 uL/hr
over 5 to 7 days. Steady-state concentration of leup1ftin in
mouse plasma during infusion of inhibitor was 3 x 10- M.
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Table .2.

Effect of Continuously Infused Ep453 On Experimental
Metastasis
Solution
Infused a
Control (PG)
Ep453 (0.08 M in
propylene glycol
(PG))

Number of Lung Metastases
per Animal

Mean
(± S.E.)

13,22,27,33,44,49,>300,>300
17,25,25,43,66,79,90,105

asolution in 0 infused into animal from Alzet mini-osmotic pumps
surgically implanted into mice. Rates of infusion were 1 uL/hr
over 5 to 7 days. Steady-state concentration of Ep453 in mouse
plasma during infusion of inhibitor was 3 x 10-7 M.
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cathepsin B on metastasis. In this experiment the plasma level of
Ep475 was 3 x 10-7 M. As shown in Table 6, this concentration of
an irreversible inhibitor of cathepsin B also had no significant
effect on the formation of metastatic lung colonies.

EFFECT

.Qr.

THROMBIN INHIBITORS .QN. METASTASIS

In experimental models for metastasis, prior evidence has
indicated that the attachment of circulating tumor cells is an
important step leading to metastasis.

Treatment with anti-

coagulation drugs or drugs which inhibit platelet aggregation have
been shown in some instances to reduce metastasis.

However, many

of these compounds have other effects in addition to their anticoagulation properties.

Since thrombin is believed to play an

important role in the attachment of circulating tumor cells and
tumor cell/platelet emboli, the specific thrombin inhibitors tboc-D-Phe-Pro-Argininal and D-Phe-Pro-Argininal were injected into
mice by the same protocols that were used for inhibitors of
cathepsin B. Injection of 50 mg/kg of t-boc-D-Phe-Pro-Argininal
was fatal to 5 of the mice in experiment 1, Table 7. This
experiment was continued using injections of 12.5 mg/kg. Because
of this toxicity, slightly lower doses of these compounds (37.5 or
25 mg/kg) were used. These doses were tolerated well by the
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Table 1Effect of i.p. Injected R-D-Phe-Pro-Argininals on Experimental
Metastasis
Experimental
Treatmenta

Number of Lung Metastases
per Animal

1.
Control
Boc-D-Phe-Pro-Argal
(1x50, then 12.5)

13,17,21,21,37,47,51
9,29,47

Mean
(± S.E.)

3o±6
28

2.

Control
Boc-D-Phe-Pro-Argal
(37.5)

1,23,33,41,54,59,121
12,25,26,31,36,48,62,79,118,180

3.
( 20 ,000 cells)
Control
Boc-D-Phe-Pro-Argal
(25)

o,o,o, 1, 1, 1,9, 10, 10
0 , 1 , 1 , 1 , 1 , 2 , 2 , 2 , 2 , 3 , 6 , 14 , 17 , 36

3. 6±1. 5
6,3±2.1

5, 6 , 6, 14, 15, 20, 21 , 36 , 36, 41 , 60,
7,18,23,24,29,38,46,62,62,64,

24±s.3
37.±6,5

4.
Control
D-Phe-Pro-Argal
(37.5)

aNumbers in () indicate mg/kg injected i.p. every 12 hours for
5.5 days. Control animals received injections of the drug
vehicle. Argal is an abbreviation for argininal.
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animals. In experiment 3 (Table 7), several of the mice (3) died
before the end of the experiment, and several were lethargic with
difficulty in hind leg motion.

Several of these animals were

autopsied and appeared normal, except ror the tumors.

In 4

animals on which complete autopsies were performed, metastases
were found outside the pleural cavity in three animals; 2 of these
were in the kidneys and one each in the lymph node and at a
subcutaneous site.

It is believed that the effects seen in these

animals were due to tumor burden, possibly due to the length of
this experiment (21 days).

Similar rear body effects on motion

were observed in animals of the control groups and treated groups.
It was also noticed that in experiment 2 (Table 7) in which the
higher dose of the t-boc-D-Phe-Pro-Argininal compound (37.5 mg/kg)
was used, the animals in the treated group appeared to have
bruises on their abdominal region.

This differed rrom the control

and leupeptin ·animals where the abdominal region toughened with
scar tissue from the repeated injections.

Some of the animals

receiving this dose (37.5 mg/kg) of the t-boc-D-Phe-Pro-Argininal
also showed susceptibility to bleeding when handled by the tail.
In Table 7 it can be clearly seen that the specific
inhibitors of thrombin had no significant effect on metastasis.
This was the result when t-boc-D-Phe-Pro-Argininal or D-Phe-ProArgininal was used, and did not vary when the number of tumor
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cells injected was decreased (experiment 3, Table 7). In fact, in

3 of the experiments (experiments 2, 3, and 4, Table 7), these
compounds showed a slight promotion effect, causing the number of
lung colonies to increase by an average of 40%.
Again, in order to make sure that the concentrations of drug

.in.Y.1.YQ. were sufficient to inhibit thrombin, the blood levels were
assayed following i.p. injection.

A 37.5 mg/kg injection of t-

boc-D-Phe-Pro-Argininal resulted in plasma levels of 1 x 10-6M
after 30 minutes and 4 x 10-7M after 1 hr.
inhibitor could be detected.

After 1 hr, no

Therefore, these experiments were

repeated using the osmotic pump procedure described previously.
Loading the pumps with a 0.25 M solution of D-Phe-Pro-Argininal
resulted in a steady state level of inhibitor at a concentration
of 4 x 10-7M.

This is higher than the Ki of this compound for

thrombin, but lower than the Ki values for the other implicated
proteases (Table 1), so that in these experiments thrombin should
be effectively and specifically inhibited.

This treatment

increased the number of lung colonies dramatically as shown in
Table 8. In two separate experiments the treated group averaged
over 300 individual lung colonies, while the control groups
averaged close to ten.
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Table

.a

Effect of Continuously Infused D-Phe-Pro-Argininal On Experimental
Metastasis
Solution
Infused a

Number of Lung Metastases
per Animal

Mean
(± S.E.)

4,4,4,6,8,9,12,13

7.5±1.3

229,>300,>300,>300,>300,>300
>300,>300,>300,>300

>300b

7,8,11,12,13,18

12±1. 4

104,>300,>300,>300,>300,>300

>300b

1.

Control (40%DMSO)
D-Phe-Pro-Argal
(0.25 M in 40%
DMSO-PBS)
2.
Control (40%DMSO)
D-Phe-Pro-Argal
(0.25 M in 40%
DMSO-PBS)

asolution in () infused into animal from Alzet mini-osmotic pumps
surgically implanted into mice. Rates of infusion were 1 uL/hr
over 5 to 7 days. Steady-state concentration of D-Phe-ProArgininal in mouse plasma during infusion of inhibitor was 4 x
10-7 M. bvalue is significantly different from control at P <
0.001. Argal is an abbreviation for argininal.
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EFFECT OF PLASMINOGEN ACTIVATOR INHIBITORS ON METASTASIS

Because of the higher Ki values of the R-Glu-Gly-Argininal
inhibitors against their targeted protease, urokinase (Table 1),
higher

.in~

concentrations of these compounds were needed to

examine their effect on metastasis. The blood level of these
compounds was measured following i.p. injections as described in
the methods section. It was found that after a 30 mg injection,
the compound was only detected (as measured by inhibition of
urokinase, lower limit 1 x 10-5 M) for 1-2 hr. Due to these
features of the R-Glu-Gly-Argininal compounds, (high Ki values,
rapid turnover i.n.Y..iYQ), it was impossible to use osmotic pumps to
deliver these compounds. Accordingly, maximum doses (30mg)
tolerated by the animals were injected i.p. every 2-4 hours for
the first 1-1.5 days. The results are shown in Table 9. The free
(tfa) Glu-Gly-Argininal compound appeared to be more toxic than
the t-boc-Glu-Gly-Argininal.

At these doses, both compounds

appeared to make the mice lethargic and somewhat stiff in motion
(in the (tfa) Glu-Gly-Argininal experiment, 2 of the smallest mice
died; these mice received a higher dose per kg and were also
clearly not as vigorous as the others before the experiments).
However all the mice recovered rapidly (within 24 hours) after the
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Table .9.
Effect of i.p. Injected R-Glu-Gly-Argininals on Experimental
Metastasis

Experimental
Treatmenta

Number of Lung Metastases
per Animal

Mean
(±s.E.)

1.

Control
Boc-Glu-Gly-Argal
(30 mg i.p. per animal;
8 times over 36 hr)

122,165,177,180,220,230,260,
>300,>300,>300
62,68,154,160,178,>300,>300

2.

Control
H-Glu-Gly-Argal
(30 mg i.p. per animal;
6 times over 25 hr)

87,89,122,122,128,149,189
214,279,>300,>300,>300

aNumbers in ( ) indicate mg/kg injected i.p. every 12 hours for
5.5 days. Control animals received injections of the drug
vehicle. Argal is an abbreviation for argininal. bSignificantly
different from control at P < 0.001.
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injections had ceased.

These inhibitors also failed to reduce

metastasis, even at the high doses used in this experiment. The
promotion of lung colonization seen in experiment 2, although
significant, must be considered with caution due to the possible
toxic side effects of the high doses of drug used in this study.

RESULTS OF PLASMINOGEN ACTIVATOR STUDIES

Because of the strong evidence for a role of PA in
metastasis, attempts were made to study the PAs secreted by the
B16 melanoma in culture.

The susceptibility of the secreted

enzyme to inhibition by the tripeptide aldehyde inhibitors

was

estimated using concentrated media prepared by different
procedures. Those reported (Table 10) were performed using an
Amicon concentrate (500 ml concentrated to 2.5 ml) and were
determined under the conditions described in methods.

Inhibition

constants were determined by measuring the rate of hydrolysis of
S-2444 in the presence and absence of inhibitor. This substrate
(S-2444) has been shown to be specific for UK with a Km of 6 x
10-5 M (Kabi). Preliminary data (Table 11, Figure 2) indicated
that although plasminogen is the only known protein substrate for
both UK and tPA, they have different specificities for small
substrates. The Km of S-2444 determined against human rt-PA was
approximately 1.5 x 10-3 M. This indicates that S-2444 is a 25fold better substrate for UK than for tPA. Thus, these Ki's give
an estimate of the susceptibility of the UK-like enzyme present in
serum-free conditioned medium (SFCM) to inhibition by the
aldehydes used in this study. Several of these inhibitors gave
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TABLE .1.Q.
Inhibition of urokinase-like activity in
concentrated SFCM by tripeptide aldehydes

----------------------------------------tripeptide aldehyde
-

K.

1

a M

- -- - - - - - - ------------------------

(tfa)Glu-Gly-Argininal

3.0 x 10- 4
(1.59 x 10- 4 , 2.64 x 10- 4 , 4.76 x
10- 4 >

t-boc-Glu-Gly-Argininal

4.o x 1o- 4
(4.5 x 10- 4 , 3.4 x 10- 4 )

DNS-Glu-Gly-Argininal

2.1 x 10- 4
(9.5 x 10- 5 , 3.2 x 10- 4 )

D-Phe-Pro-Argininal

9.8 x 10- 5
(1.43 x 10- 4 , 5.37 x 10-5)

t-boc-D-Phe-Pro-Argininal

2.5 x 1o- 6
(9.3 x 10-7, 4 x 10-6)

leupeptin

1.6 x 1o- 4

c3 x 1 o- 4 , 2.59 x 1 o-5)

------- -------------

a Inhibition constants were determined in 1.1 mls. 0.05 M tris pH
8.8 containing 30 KIU of aprotinin and 100 ul concentrated S~CM.
Substrate (S-2444) was at a final concentration of 1.1 x 10- M.
The Ki is the average of the individual values in parentheses.
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Table l l

Determination of

SUBSTRATE
M x 103

~

of S-2444 for rtPA

INITIAL RATE {v)a
M/min. x 107

S/v
min x 10- 4

3.6

3.3

1•1

1. 82

2.7

0.67

0.91

1. 7

0.54

0.45

1. 1

0.41

--a-Rea~ti~;s were pe;for;;d i;-~-ri~~l volume of 1.225 mls. of
0.05 M tris buffer pH 8.8, using a stock substrate solution of 1 x
10- 2 M and 25 ul of a 0.1 mg/ml solution of rtPA. See Figure 3 for
plot of data.
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Figure 2. Determination of Km of S-2444 for rtPA.
A plot of S/v vs. S gives a straight line with a
correlation coefficient of 0.99 by linear regression.
From the Hanes plot, S/v = Km/V
and the intercept

1.5 x 10-3 M.

= Km/V,

+

S/V, the slope = 1/V

giving a Km of
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similar Ki's against this preparation, but in this crude
preparation it is probable that more than one enzyme was taking
part in the reaction.

Electrophoresis gels of the concentrated

media showed many protein bands, and when overlayed on fibrin agar
indicator gels, several bands of lysis were observed.
clearly illustrated in Figure 3.

This is

No lysis was observed in fibrin

plates in which the plasminogen had been denatured.

These bands

varied in appearance but always consisted of a combination of the
three shown in Figure 3. These bands could be interpreted in
several ways (partially degraded forms, different enzymes, enzyme
inhibitor complexes), but it is now clear that they represent
synthesis of both types of PA (tissue and urokinase) by the B16
cells.
In order to obtain a better estimate of these Kis, several
attempts were made at purifying the enzyme; these were hampered
principally by the low amounts of activity present in the initial
starting material.

Serum free conditioned media contained

approximately 4000 to 5000 mU/L

of UK-like activity as measured

by S-2444 hydrolysis. Attempts to grow cells in SFM for extended
lengths of time or in media containing serum supplements proved
unsatisfactory, and the small amounts of conditioned media
obtained by traditional cell culture were inadequate for detailed
study.

After initial attempts using a peptide aldehyde column,
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Figure 3. Photograph of electrophoresis gel
stained in Coomassie Blue after overlaying on fibrin
agar indicator gel. Sample was concentrated B16
melanoma SFCM.
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the use of a p-aminobenzamidine column was found to result in
reproducible binding of the enzyme activity.

After several

modifications were attempted, the purification procedure outlined
in the methods section was used to produce a preparation which
produced a single major band of lysis following gel
electrophoresis and zymography on a fibrin-agar plate (Figure 4).
Mouse urine (25 ul) was electrophoresed in an adjacent lane, and
produced two bands of lysis corresponding to the low (30,000) and
high (48,000) molecular weight forms of urokinase. Samples were
always electrophoresed in triplicate and the gels were sliced into
three equal sections. One of the gel sections was stained in
Coomassie Blue. The two remaining sections were prepared for
zymography. One was overlayed on a fibrin-agar gel to detect PA
activity and the other was overlayed on a fibrin-agar plate in
which the plasminogen had been denatured to control for
plasminogen independant lysis. No lysis was observed on the
control plates. It is clear from the position of the lysis bands
that the sample (50 ul) contained a qualitatively different
plasminogen activator. From the position of mouse tissue type PA
(see Figure 5), it was concluded that the majority of the PA
activity in the partially purified sample was of the tissue type.
This single-step chromatography procedure resulted in a yield of
about 30% and about a 100-fold purification, although these
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Figure 4. Photograph of fibrin agar underlay
showing bands of lysis produced by overlaying with
electrophoresis gel containing samples of partially
purified B16 PA (lanes 1 and 2) and mouse urine (lane

3).
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numbers are based in S-2444 hydrolysis activity and the protein
determinations were obtained in the presence of detergents and
high concentrations of other materials. A second preparation
purified from a different batch of SFCM, resulted in a single band
of lysis when electrophoresed and overlayed on a fibrin-agar
plate.

This single partially purified activity is shown clearly

in Figure 5, where samples of concentrated SFCM, partially
purified PA from SFCM, mouse urine, and mouse lung homogenate were
electrophoresed on the same gel.

Mouse urine is known to contain

only UK and mouse lung is known to show tPA and UK PA activity.
Comparing these "standards" to the B16 samples, it is clear that
both enzymes are present in the sample of concentrated medium
while the partially purified preparation only shows a tPA band.
The Coomassie Blue stained gel is shown for comparison in Figure
6.

That this preparation consisted solely of tPA was demonstrated

by showing that the plasminogen activator activity was completely
inhibited by anti-tPA antibody and completely resistant to anti-UK
antibody. After incubation with the specific antibody preparation,
samples were assayed for their ability to activate plasminogen and
produce lysis on a fibrin-agar plate. The result is shown in
Figure 7, which was photographed 5 days after the samples were
applied. The complete inhibition of lysis by anti-tPA antibody
clearly indicates that this sample contained only mouse tPA.
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Figure 5. Fibrin agar underlay showing bands of
lysis produced by electrophoresing mouse urine (lane
1), concentrated B16 SFCM (lane 2), partially purified
PA from B16 SFCM (lane 3), and homogenized mouse lung
tissue (lane 4). This pattern of lysis did not change
after five days.
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Figure 6. Stained electrophoresis gel
corresponding to that overlayed in figure 15. Samples
are urine (lane 1), concentrated SFCM (lane 2),
partially purified PA from B16 SFCM (lane 3),
homogenized mouse lung tissue (lane 4), and molecular
weight standards (lane 5). Molecular weights of
standards are: a= 92,000, b = 66,000, c = 45,000, d =
31,000, e = 25,000, and f = 17,000.
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Figure 7. Antibody inhibition of lysis on fibrin
agar indicator gel by partially purified PA from B16
SFCM. Wells 3 and 6 are controls, wells 2 and 5
contained anti-tPA antibody, and wells 1 and 4
contained anti-UK antibody.
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Direct activation of plasminogen by a partially purified
preparation of mouse tPA using the coupled plasminogen-S-2251
assay is shown in Figure 8. The effect on this activation by
pretreatment with the irreversible inhibitors DFP and pCMB is also
shown.

DFP completely inhibited the activity of the mouse tPA

sample, while pCMB had no effect. These inhibitors gave the same
result when the hydrolysis of the synthetic substrate S-2444
(Figure 9) was measured.

These results confirm the serine-type

nature of the isolated PA activity.

Inhibition constants for the

tripeptide aldehydes determined against this partially purified
preparation are listed in Table 12.
Inhibition constants for a purified sample of recombinant
human tPA (rtPA) were also obtained under the same conditions.
These are shown in Table 13. An example of the inhibition
experiments is shown in Figure 10. It can be noted that the
specificity of the inhibitors against this purified preparation of
human rtPA, consisting of a mixture of one and two chain forms,
follows the same pattern as that for the partially purified PA
preparation from the B16 melanoma.

These results indicate that

tPA (Table 13) has a very different specificity towards small
peptides than urokinase (Table 1), even though their natural
substrate is identical (plasminogen).
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Figure 8. Spectrophotometer tracing showing the
direct activation of plasminogen by a partially
purified preparation of B16 melanoma PA and the effect
of DFP and pCME. The control reaction is shown in A),
inhibitjon by DFP is shown in B), and lack of an effect
of pCMB is shown in C). Arrow indicates point of
addition of UK to verify DFP treatment was not
inhibiting
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Figure 9. Spectrophotometer tracing showing the
hydrolysis of S-2444 by a partially purified
preparation of B16 melanoma PA before and after
incubation with the irreversible pr·otease inhibitors
DFP and pCMB. A) is the control reaction, B) is after
treatment with DFP, and C) is after treatment with
pCMB.
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TABLE .1Z.
Inhibition of a partially purified preparation
of B16 melanoma tPA by tripeptide aldehydes.

-------tripeptide aldehyde

Ka
i

----------

(tfa)Glu-Gly-Argininal

1.1 x 10-2

t-boc-Glu-Gly-Argininal

7.5 x 10-3

DNS-Glu-Gly-Argininal

1.6 x 10-3

D-Phe-Pro-Argininal

8.3 x 10-5

t-boc-D-Phe-Pro-Argininal

5.5 x 10- 6

leupeptin

3.3 x 10- 4

aKi s were esti;;ted -i~-~ -ri~~i-vo~~;;-~r-1~1- ml~-0.05 M Tris-0.025
M EDTA pH 8.8 containing 1.1 x 10- M substrate (S-2444). 100 ul
of the enzyme solution was incubated with the inhibitor to be
tested and 30 K!U aprotinin in buffer for 15 minutes before the
reaction was started by addition of substrate.
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TABLE 11
Inhibition of human rtPA by tripeptide aldehydes
tripeptide aldehyde

K.a M

(tfa)Glu-Gly-Argininal

.3.J

1

x .iQ3

3.97 x 10- 4 b (2)
1.19 x 10-3 b (2)

3.34 .± 0.64 x 10-3 c
3.33 .± 0.10 x 10-3 c

t-boc-Glu-Gly-Argininal
5.1 x 10- 4 b (2)
2.05 x 10- 4 b (2)
DNS-Glu-Gly-Argininal

1.85 .± 0.11 x 10-3 c
1.66 .± 0.35 x 10-3 c

Ll x

.w.=53.19 .± 0.3 x 10- 5 c
2.39 .± 0.05 x 10-5 c

6.36 x 10-56 b (3)
6.36 x 10- b (3)
D-Phe-Pro-Argininal
8.97 x 10-5 b (2)
3.59 x 10- 5 b (3)
t-boc-D-Phe-Pro-Argininal

1.78 ± 0.07 x 10-5 c
1.60 ± 0.09 x 10-5 c

Ll..

x 1Q:=1.

1.24 x 10- 6 b (3)
1.24 x 10-7 b (3)
leupeptin
4.6 x 10-5 b (3)
1.84 x 10-5 b (3)

1.88 + 0.09 x 10-7 c
2.35 :±: 0.2 x 10-7 c

-9...R ~

1o=28. 92 ± 0.32 x 10-~ c
9.44 ± 0.21 x 10- c

a is the average of two Ki values obtained using the two
inhibitor concentrations designated as b. The individual Kj
values designated as c, are shown.± standard deviation. (NJ i~
the number of experimental runs.
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Figure 10. Spectrophotometer tracing showing the
inhibition of rtPA activity by D-Phe-Pro-Argininal. A)
is the control 1 B), C), and D) were in the presence of
3.6 x 1o-5 M D-Phe-Pro-Argininal.
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DISCUSSION

Metastasis can be envisioned as a series of individual steps,
although it is not necessary to assume that the tumor cells which
metastasize participate in each of these.

To metastasize, the

cells of a growing tumor must invade through normal tissue.

This

would often include degradation of a fibrin capsule found around
many primary tumors which is apparently formed outside the
circulatory system.

When the tumor cell reaches a blood vessel,

or induces the formation of its own vascular system, it must
degrade the basement membrane and intravasate into the
circulation.

The tumor cells in circulation must then attach to

the endothelium or subendothelial matrix, again degrade the
basement membrane, and extravasate into the normal tissue.

Here

the tumor cell(s) will divide and grow into a secondary tumor
mass.

It should be clear that the model used here only tests the

hypothesized roles for proteases in the steps following the
release of tumor cells into the circulation.

Thus the roles of

proteases in increasing the survival of tumor cells in
circulation, the attachment of these cells, and the invasion of
these cells into normal tissue from the bloodstream will be
considered here.
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The experiments reported here utilized the B16-F10 melanoma
cell line, which was selected for its high potential to form lung
colonies after i.v. injection.

The B16 melanoma system,

originally described by Fidler (1973), was chosen for these
experiments for a number of reasons. Principle among these was the
fact that the B16 melanoma developed spontaneously in the C57Bl6
mice which are used in the experimental model. By using a natural
tumor line in a syngeneic host, no assumptions about the role or
the immune system need to be made, and the model is perhaps more
relevant to the natural disease condition. Also, this cell line
has been used in many studies and some of the correlations/
contradictions or increased protease and increased metastasis were
performed on sublines of the original B16. This tumor also
metastasizes spontaneously so the current study could easily be
expanded to include the initial steps in metastasis. In addition,
the use of mice instead of rats or guinea pigs allowed the total
amount or the difficult to synthesize aldehydes to be kept
reasonable.
However, the model must be considered in terms of the work
proposed. The aim of this research was to test the hypothesis that
certain proteases participate in the processes or attachment
(thrombin) and invasion (cathepsin B, plasminogen activator) of
circulating tumor cells. It is clear that following i.v. injection
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of tumor cells they must first arrest in the lungs and then
extravasate into the lung parenchyma in order to develop into
metastases. Therefore, the model does include the relevant steps
of the metastatic process under study, and agents can be tested
for their effects on this process. Another aspect of the model
which must be considered is the ability to determine whether or
not a specific treatment is producing an effect. In this work, a
change in the number of metastatic colonies would be considered
evidence of an effect on the metastatic process. Therefore it is
important that the method for determining the number of lung
colonies be accurate and reproducible. As stated by Fidler (1978),
and discussed in the references therein, most lung tumors in mice
appear on the surface and can be counted with a dissecting
microscope. In two of these studies (Wexler, 1966; Wood
~al,

1953), detailed microscopic examination of lung sections

were compared to observations of surface colonies and found to
give similar results. Thus prior evidence indicates that
the enumeration of surface lung colonies would give an accurate
indication of the total number of metastases, and any significant
changes in the average number of metastases would be detected by
this procedure (for example, see Figure 11). However, the
treatments used in these experiments may result in an altered
distribution of metastases, either within the lung or to other
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Figure 11. Photograph illustrating lung lobes
dissected into Jobes for counting of metastases. The
upper lung (row a) contains > 300 individual metastatic
colonies, while the lower lung (row b) only contained
7. Animals were selected from those shown in table 5.

a

b

_.
I\)
I\)
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organs. The absence of extrapulmonary metastases was routinely
verified by gross autopsies. However, in order to address the
possibility of an altered distribution of metastases within the
lung, two alternate possibilities have been considered. The first
method, which has

been~ed

to study the initial arrest of tumor

cells in organs (Fidler 1978), involves radiolabeling of the tumor
cell innoculation with 11 2 5 2-iodo-deoxy-uridine. This procedure
may have resulted in a more accurate determination of the number
of injected tumor cells remaining in the lungs, and should be
considered for future experiments. Another possibility when
working with melanoma cells would be to use melanin as a measure
of metastasis. This procedure has not been reported in the
literature, and so would require preliminary evidence to verify
its' usefulness. Also, the presence of amelanotic nodules in some
experiments (as observed in this work) may result in difficulties
in interpretation or in comparisons between experiments. Melanin
is also a difficult compound to extract from tissue, requiring
repeated refluxing in 6 N HCL (Jimbow

~.al..,

1984).

The number of metastases varied between control groups in the
experiments reported here.

This probably was a result of using

animals from different vendors, using cells which had been
maintained in culture for different lengths of time, and
inadvertant differences in the exact stage of growth and treatment
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of the tumor cells when injected.

Because the control for each

experiment was always performed identically to the experimental
group, this variation in average number of lung colonies should
not affect the conclusions of this work. In addition, as stated
above, the agents used are being tested for their ability to
inhibit the attachment and invasion of the injected tumor cells.
Since every tumor cell which develops into a metastases must
complete these steps, it is the relative number of successful
metastases between control and experimental animals which is
important to consider, not the total number.
In this work, tripeptide aldehydes were used to inhibit the
proteolytic enzymes cathepsin B, PA, and thrombin in an in...Y.i:l.Q.
model for metastasis. These compounds have been shown to be potent
and specific inhibitors of these enzymes .in yitro. Treatment of
animals with these inhibitors in a model for experimental
metastasis would be expected to give clear evidence as to the
importance of the inhibited enzymes in metastasis. For example, if
leupeptin is the only compound to inhibit metastasis, it would be
a strong indication that cathepsin B is involved. Alteratively, if
D-Phe-Pro-Argininal is the only compound to inhibit metastasis, it
would support the hypothesis that thrombin is important to the
lodgement of i.v. injected tumor cells and thus is a crucial
participant in the process of metastasis. If both D-Phe-Pro-
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Argininal and leupeptin produce a significant reduction in
metastasis, it would indicate that cathepsin B and thrombin are
important to the process of lung colonization. Or if these
inhibitors reduced metastasis when used at higher concentrations,
plasmin might be suggested to play a role in metastasis. By using
a group of similar enzyme inhibitors of known specificity, it will
be possible to clearly evaluate the effects of inhibiting specific
enzymes on the metastatic process. This contrasts some of the
earlier studies which used general protease inhibitors or
inhibitors of unknown specificity.
As noted above, cathepsin B has been implicated as an enzyme
capable of much extracellular tissue destruction, including the
degradation of type IV collagen.

The production of high levels of

cathepsin B has been shown to correlate with high levels of
metastasis, and previously was believed to play a role in the
coagulation and platelet aggregation of circulating tumor cells.
If a cathepsin-B like protease is crucial to the metastatic
process, then inhibition of its activities should lead to a
reduction of metastasis.

In the experiments reported here, this

is clearly not the case.

Using the strong cathepsin B inhibitor

leupeptin, and following a protocol which was reported in the
literature to result in significant reduction of metastasis, it
was repeatedly demonstrated that in the B16 melanoma system used,
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leupeptin produced no significant reduction (Table 2).

Because

the concentration of leupeptin following i.p. injection was found
to be changing rapidly with time, these experiments were repeated
using mini-osmotic pumps to maintain the concentration of
leupeptin at a steady state level above the Ki of cathepsin B but
below the Ki of other proteases for which there is a significant
amount of evidence to support a role in metastasis.

In these

experiments therefore, the effect of leupeptin should be to
selectively and efficiently inhibit cathepsin B. In previous work
using leupeptin, the

.1.n.~

concentration was not determined.

From the turnover data reported here, it is clear that following
i.p. injection of leupeptin, many proteolytic enzymes would be
inhibited. Thus these prior experiments (Saito

~.al..,

1980) do

not conclusively indicate the involvement of a particular
protease. Again, in my experiments there was no reduction in lung
colonies in the treated group versus the untreated (Table 5).
Finally, both the injection and osmotic pump studies were repeated
with a second potent inhibitor of cathepsin B, Ep453.

This

irreversible inhibitor, at the concentration used (3 x 10-7 M),
would inhibit any soluble cathepsin B in the circulation. These
experiments also failed to show any significant reduction of
metastasis (Table 6).

Taken together these results give strong

evidence against an essential role for cathepsin B in the process
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of lung colonization by B16 melanoma cells.

These results are in

agreement with previous experiments using leupeptin and pepstatin
which also failed to show a reduction in metastasis, although
these did not report the .i.n..Yi.Y.Q. concentration of inhibitor
(Giraldi tl.al.., 1977c; Harvey tl.al.., 1977).
There are at least two explanations for these results which
would still be consistent with a role of cathepsin B in metastatic
processes.

First, the cathepsin B may not be completely inhibited

by the circulating drugs.

This may be possible if the circulating

tumor cells attach to the substrate to be degraded first and then
use a membrane bound form of cathepsin B to degrade it.

For

example, the cells may attach to the endothelium of small
capillaries in the lungs and then utilize a membrane bound form of
cathepsin B to degrade the basement membrane.

Liotta and others

(Terranova tl.al., 1984) have shown the importance of tumor cell
attachment to the process of metastasis. It has also been shown
{Quigley

tl~,

1986) that when transformed cells are grown in

contact with a normal subendothelial matrix, their degradation of
this matrix cannot be completely inhibited by small protease
inhibitors. In addition, under certain experimental conditions,
enzymes are not susceptible to inhibition by protease inhibitors
(Campbell tl .al.., 1982; Steven tl .al.., 1982).

This could also

apply to an extracellular enzyme secreted locally at the point of
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degradation.

In these localized extracellular spaces, the

cathepsin B may be extremely resistant to soluble inhibitors.
This could be due to the close localization of substrate and
enzyme, which has the effect of increasing the substrate
concentration.

Because peptide aldehydes act as competitive

inhibitors, at a high enough substrate concentration, their effect
can be negated. Leupeptin has been shown to be ineffective at
inhibiting B16 melanoma invasion in the amnion model at
concentrations 100-fold higher than the Ki for UK, but antibodies
against UK are effective inhibitors in this system (Rifkin, 1986).
However, leupeptin has been shown to be effective at inhibiting
intracellular degradation of proteins, and especially intralysosomal proteins

(Salminen~ .al,.,

1984).

The substrate

concentrations in the lysosome would be expected to be quite high,
and therefore it is unclear as to how an extracellular enzyme
would not be inhibited at the levels of leupeptin (3 x 10- 6 M)
used in this experiment (Table 5).

In addition, leupeptin has

been shown to be effective at reducing protein degradation in
models for muscular dystrophy (Sher
doses than those used here.

~.al_.,

1981) at much lower

The use of two inhibitors with

different mechanisms of action and properties also argues against
the suggestion that cathepsin B is not inhibited in these
experiments.

A second possibility is that other enzymes, such as
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PA, can degrade the same substrates as cathepsin B.

For example,

even if cathepsin B is inhibited 99%, tumor cell secreted UK may
still be able to activate collagenase and degrade the basement
membrane so that the overall process of metastasis is not
inhibited.

In this case increased cathepsin B might be involved

in metastasis but may not be essential, or may not be involved in
the rate limiting step. Another alternative is that increased
release of cathepsin B-like enzymes may just be a phenotypic
aberration of tumor cells.

In addition, these experiments do not

rule out a role of cathepsin B in the growth, invasion, or
metastasis of the primary tumor.

It is interesting to note that

in the experiments which utilized injections, we did in one
example note a statistical decrease in lung colonization, and
consistently observed a reduction in the average number of lung
colonies.

It can be postulated that the high initial

concentrations of leupeptin are inhibiting other proteases which
are essential to the metastatic process.

However, because the

concentration of leupeptin drops rapidly, the enzyme is not
inhibited long enough to significantly reduce metastasis.

This

might provide a partial explanation for the disagreement between
the data reported here and that of Saito
.al_.

~,al..

(1980). Saito

~

(1980) (using a different tumor line) report that leupeptin

administered i.p. resulted in a decreased number of pulmonary
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emboli following i.v. injection of tumor cells, and attributes
this to the inhibition of thrombokinase.

At the high initial

concentration of leupeptin, factor Xa would be inhibited, as well
as other enzymes.

The effect of leupeptin on metastasis at

concentrations higher than those used here should be investigated
further. In other experiments, leupeptin has had mixed effects,
but the concentrations .in.Yi.YQ. were not previously reported so that
any conclusions from these experiments must be considered
speculative.
Treatment of experimental animals with the specific thrombin
inhibitors R-D-Phe-Pro-Argininal by the i.p. protocol resulted in
no significant change in the number of metastases, whereas
administration of these compounds by the continuous infusion
method resulted in a dramatic and significant increase in
metastases.

Again referring to the data of

Saito~ .al,

(1980),

inhibition of thrombin activity would also be presumed to block
the action of factor Xa on increased fibrin formation.

The

observation of an increased number of pulmonary nodules after
treatment with a thrombin inhibitor contradicts a large body of
evidence which supports the idea that fibrin formation and
platelet aggregation are important steps in the process of
successful blood borne metastasis.

However, as discussed above

most of the previous studies used coagulation inhibitors which had
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many other effects in addition to inhibition of thrombin activity.
Also, tumor cells have been shown to attach to endothelial cells,
subendothelial matrices, and aggregate platelets (Tohgo
1985) without the formation of fibrin.

~ .ai_.,

Fibrin formation therefore

may be a consequence of other properties of metastasizing tumor
cells, again without being essential to the process.

It has been

proposed that fibrin around a circulating tumor cell may be part
of the host response in an attempt to keep the tumor cell from
extravasating. Fibrin could then be proposed to play a similar
role of preventing invasion of the circulating tumor cell and of
the primary tumor. It is also possible that thrombin has other
suppressive roles in metastasis so that inhibition of this enzyme
leads to a promotion of experimental metastasis.

Thrombin can not

only catalyze the formation of fibrin and stimulate the secretion
of inhibitors of fibrinolysis, but when bound to thrombomodulin
(an endothelial cell surface protein found throughout the
circulation

(Ishii~ .al,..,

1986)) can also cause the activation of

the fibrinolytic pathway. However, thrombin bound to
thrombomodulin is rapidly internalized and degraded, and an
inhibitor of activated protein C has also been described (Esmon,
1983). In addition, Gelehrter and Sznycer-Laszuk (1986) showed
that the direct effect of thrombin on endothelial cells was an
increased secretion of PA inhibitor relative to PA, and hence a
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decreased fibrinolytic activity. Also, some of the evidence which
supports an enhancing role of thrombin and fibrin formation in
metastasis is based on the direct observation of fibrin-containing
tumor emboli in the target organs. Thus although the many diverse
actions of thrombin can not be ignored, it's net effect in the
process of blood-borne metastasis appears to be the formation of
fibrin and a tumor cell embolus. Therefore, the net effect of a
thrombin inhibitor should be to inhibit the formation of fibrin
and tumor cell emboli. In the experiments reported here, the
continuous inhibition of thrombin by infusion of D-Phe-ProArgininal at a steady-state concentration of 4 x 10-7 M resulted
in a significant increase of lung metastases following i.v.
injection of tumor cells (Table 8). This would indicate that
thrombin and presumably fibrin formation have an inhibitory effect
on metastasis.
It would be informative to examine the lungs of mice treated
with D-Phe-Pro-Argininal at various times after the injection of
the tumor cells, and compare the number of tumor emboli and the
amount of associated fibrin with that found in untreated mice.
Alternatively, the D-Phe-Pro-Argininal compounds may be having
other effects. For example, the inhibition of thrombin may be
resulting in a damaged endothelial cell layer, which would
facilitate greater tumor cell attachment and invasion. In future
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investigations, monitoring of the coagulation state of the animal
may be useful to obtain a balance between inhibition of tumor cell
attachment and other possible effects on the animal. Further
research on the 1.n YiYQ effects of this compound is also
necessary.
The experiments using the R-Glu-Gly-Argininals to inhibit UK
are not as conclusive as the experiments in which inhibitors of
thrombin and cathepsin B were used. Because of the high Ki values,
large amounts of these drugs had to be injected and this may have
produced toxic effects. In addition because of the large amounts
of these compounds needed and the limited capacity of the osmotic
pumps, the osmotic diffusion pumps could not be used which
resulted in a much shorter period of drug treatment in these
experiments. However, if UK were required for tumor cell
metastasis in this initial period (1.5-2 days after tumor cell
injection), it would be expected that the concentrations of UK
inhibitors used in this experimental procedure would have.resulted
in a reduction in metastases. In the t-boc-Glu-Gly-Argininal
experiment (Table 9), the number of lung colonies was similar in
the treated and control groups, and in the (tfa)Glu-Gly-Argininal
experiment there was a significant promotion of metastasis. The
free compound appeared to produce more toxic effects than the tboc compound, and so this promotion of metastasis should be
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considered with caution.
The failure of UK inhibitors to reduce metastasis in these
experiments can be explained by the same rationale used to explain
the lack of an effect of cathepsin B inhibitors on metastasis (see
above). Again, UK has been shown to exist in an active membrane
bound form which may be resistant to inhibition after the cell is
bound to the extracellular substrate (Vassall!

~.al,,

1985). In

addition, only a small amount of active UK is necessary to quickly
activate a significant amount of plasminogen, especially if the
whole process occurred on the surface of a fibrin clot surrounding
a tumor cell. Also, PAs may not be essential to tumor metastasis,
but may play a role which can be fulfilled by another substituting
protease, such as cathepsin B. These experiments also do not
address the participation of PAs in the invasion and spread of the
primary tumor.
A further complication of these experiments comes from the
demonstration that the B16 melanoma produces both the tPA and the
UK PA. Although melanoma cells seem to be unique in their
increased production of tPA, and UK is generally considered to be
the enzyme involved in tissue degradation and the invasion and
metastasis of tumors, this is partially an assumption and must be
proven. In the experiments reported here, the tPA from the
melanoma cells would not have been significantly inhibited even at
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the high doses of inhibitor used. Thus it may be that the B16
melanoma uses the tPA to facilitate extracellular degradation and
metastasis, or it may use both, with either enzyme alone being
sufficient to complete the metastatic cascade. The experiments
reported here would still indicate that UK is not an essential
participant in the lung colonization process.

The production of PAs by the B16 melanoma has been correlated
to the metastatic potential of this tumor cell line (Wang

~.al_.,

1980). There have also appeared contradictory reports which show a
lack of correlation

(Nicolson~

.sU..., 1976).

Because of the

strong evidence for a role of PAs in processes of invasion and
metastasis, it was of interest to investigate the PAs produced by
the B16 melanoma in culture.

It was determined, by zymography and

antibody studies, and confirmed by results from other laboratories
(D. Belin, personal communication), that the B16 melanoma in
culture produces both types of PAs, the tissue and urokinase type.
In earlier experiments, i.e. Figure 3, recovered activity appeared
to be largely UK type.

In more recent experiments, (Figure 5),

approximately equal amounts of both types of enzyme were present.
This could represent a change in the phenotype of the cells due to
the time which they have been maintained in culture or this could
be due to changes in the procedure which resulted in preferential
recovery.

Other researchers have also reported varying amounts of

synthesis of the two types of enzymes by B16 cells (D. Belin,
personal communication).

This situation could account for some of

the contradictory evidence reported for the correlations of PA and
metastatic potential in this cell line.

If UK is the enzyme

active in metastasis, measurements of total cellular or secreted
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PA activity would not give a proper result since these
would include the tPA activity (Camiolo and Greco, 1986).
Measurements of secreted enzyme may also not correlate with
metastasis, because in these and other experiments there is some
indication that it is the membrane-bound proteases which actually
participate in the local processes of tumor invasion.

This

situation is further complicated since both enzymes exhibit
different activities in the presence and absence of fibrin, and
exist in a variety of active forms which also differ in activity.
Instead, antibody studies need to be performed which correlate the
metastatic potential of a group of cells directly with a specific
PA activity, for example, cell-associated UK activity.
Because of the evidence suggesting that PAs are involved in
the process of metastasis, it was of interest to study the PAs
produced by the B16 melanoma. Inhibition constants were determined
for a crude preparation of concentrated media using the UK
specific substrate, S-2444 (Table 10).

This substrate was shown

by Km values to be approximately 10-fold better for UK over tPA,
and in the concentrated media, other proteases were probably
present which were not completely inhibited by the concentration
of aprotinin used (30 KIU/ml).

Therefore these Ki values only

give an estimate of the inhibition of UK-like activity by the
peptide aldehydes used.

It has been shown by gene sequencing
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however, that the UK type enzyme is very similar between species
(Belin~

.aJ..., 1985).

Therefore the inhibition constants obtained

for human UK can be used as an indicator of the selectivity and
effectivness of the tripeptide aldehydes against melanoma UK in
the ..i.n YiY.Q. experiments.
Attempts to purify the enzymes were hampered largely by the
low amounts of PA present in conditioned media.

In preliminary

experiments, the use of a Gly-Gly-Argininal (Patel
column was attempted with limited success.

~.al..,

1983)

Because of the

different specificity of tPA and UK (see below) it is probable
that part of this result is due to the low affinity of tPA for
this sequence.
used.

For this reason, a p-aminobenzamidine column was

Because of large amounts of secreted melanin in original

SFCM preparations, it was found useful to pass the medium through
a DEAE-Sephadex column prior to the affinity resin.

In this way

melanin and possibly other contaminants were removed and the
benzamidine column could be continuously reused.

Further

purification of the PAs was attempted using aprotinin and soybean
trypsin inhibitor affinity resins, G-25 Sephadex, and HPLC
columns. Again, the low amounts of activity made these studies
difficult, and in several experiments the enzyme activity was
unstable.
The Ki values for the partially purified PA prep shown in
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Table 12 show that the tPA has a markedly different specificity
for small substrates than UK.

This preparation was shown to

consist only of tPA by the migration pattern on SDS-gel
electrophoresis and the antibody study shown in Figure 7.

It was

shown to be able to activate plasminogen directly by the fibrin
plate and the coupled plasminogen-S-2251 assay.

The lack of

hydrolysis of S-2251 or of significant inhibition by aprotinin is
an indication of purity, at least of plasmin or other trypsin like
proteases.

The activity of this preparation was completely

abolished by DFP and was not altered by pCMB, evidence for the
serine type nature of the enzyme.

The Ki values follow the same

specificity pattern as those obtained for purified rtPA listed in
Table 13. The Ki value for DNS-Glu-Gly-Argininal agrees with the
Ki value of

> 9 x10- 6 M for DNS-Glu-Gly-Arginine-

chloromethylketone reported by Genetech (D. Higgins, personal
communication to Dr. Schultz).

It will be noticed that the

absolute values differ by about an order of magnitude between the
rtPA and the partially purified B16 melanoma tPA.

This is

possibly due to the impurity of the B16 preparation.

It may also

be due to differences in the amount of one chain, two chain or
partially degraded enzyme present.

From these data it can be

concluded that the murine PAs are similar to the human and that
the B16 melanoma is a relevant model for human melanoma in that
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both lines produce tPA. It is also clear that the i.n

~

inhibitor studies did not involve inhibition of tPA and so the
role of UK was tested independently.

Further studies need to be

done in order to develop different compounds to be used as
specific inhibitors of tPA, so that the role of tPA and UK can be
assessed independently and jointly.

SUMMARY AND CONCLUSIONS

Proteolytic enzymes are believed to have an essential role in
the complex process of metastasis. Much prior evidence has
accumulated which supports the theory that an increase in
proteolytic enzymes results in an increased metastatic potential.
However, these experiments often consist of indirect correlations,
such as a comparison of the amount of protease secreted by tumor
cells in culture and their metastatic potential

J..n.~.

In this

work, direct inhibition of three of the proteinases believed to be
involved (cathepsin B, urokinase, and thrombin) has been
investigated as a means of clarifying the role of specific enzymes
in this complex process, with the long-range goal of identifying
sites of possible therapeutic intervention. Inhibitors of
cathepsin B (leupeptin, Ep453), thrombin (R-D-Phe-Pro-Argininals),
and urokinase (R-Glu-Gly-Argininals), were used to treat C57BL6
mice which were injected i.v. with B16-F10 melanoma cells to model
the later stages of metastasis.

These inhibitors have been shown

J..n yitro to be potent and selective at inhibiting the proteolytic

enzymes under investigation. Inhibitors were introduced by i.p.
injection or continuous infusion using Alzet mini-osmotic
diffusion pumps. Injection of inhibitors resulted in rapidly
141
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changing drug levels, while infusion of inhibitors resulted in a
constant, steady-state plasma level of drug for at least 5 days.
The plasma level was at a concentration

specific for the targeted

proteinase. This is a significant improvement over previous
studies of this type, which utilized general proteinase inhibitors
of undefined specificity and did not determine the inhibitors' .in
.Yi.YQ. concentration. Under these conditions, inhibitors of

cathepsin B, at concentrations orders of magnitude

higher their

Kis', sho-wed no effect on metastasis by any of the pr·otocols and
dosages used. The conclusion from this work is that a cathepsin Blike enzyme is not essential to the process of lung colonization
even though much .in vitro work has implied that cathepsin B is
involved in metastasis. Injection of inhibitors of urokinase also
had no clear effect, suggesting that secreted UK may not be
essential to the colonization process. However, continuous
infusion of the specific thrombin inhibitor at levels higher than
it's equi1ibrium Ki, resulted in a large significant increase in
metastasis (300 vs. 10 lung colonies). This implies that the
formation of ribrin by thrombin may have a retarding effect on the
later stages of the metastatic process, in contradiction to much
current literature which suggests thci.t fibrin formation by
thrombin acts to increase the attachment of circulating tumor
cells in the target organ. The experiments reported here did not

143
addresr: the role of pr·ot.eases in the initial stages of metastasis,
and further studies of this type are necessary to clearly identify
the roles of proteolytic enzymes in the complete metastatic
process.
Studies of conditioned medium from B16-F10 cells grown in
culture revealed, by zymography and antibody tests, varying
amounts of tissue type and urokinase type plasminogen activators.
The tissue type

plasminogen activator was isolated and compared

to purified human recombinant tissue type plasminogen activator
for sensitivity to inhibition by a series of tripeptide aldehydes.
The two enzymes were found to exhibit similar specificity, with tboc-D-Phe-Pro-Argininal being the best inhibitor. This differs
from the urokinase type enzyme, which was most sensitive to the
sequence Glu-Gly-Argininal. These results indicate the need to
develop specific inhibitors for UK and tPA in order to further
examine their possible roles in metastasis .1n Yi.Y.Q,.

REFERENCES
Andreasen, P.A., Nielsen, L.S., Grondahl-Hansen, J., Skri ver, L.,
Zeuthen, J., Stephens, R.W., and Dano, K., Inactive proenzyme to
tissue-type plasminogen activator from human melanoma cells,
identified after affinity purification with a monoclonal antibody.
~ 3.:51-56 ( 1984).
Aoyagi, T, Wada, T., Umezawa, K., Kojima, F., Nagai, M., and
Umezawa, H., Relation between .1.n Y1.Y.Q. effects and .1.n yitro effects
of serine and thiol proteinase inhibitors • .s1..._ Pharm. ~
.2.:643:653 ( 1983).
Bajusz, S., Barabas, E., Tolnay, P., Szell, E., and Bagly,
Inhibition of thrombin and trypsin by tripeptide aldehydes.
.s1..._ Peptide Protein ~.lZ.:217-221 (1978).

~

Bayliss, M. T., and Ali, S.Y., Studies on cathepsin Bin human
articular cartilage. Biochem • .s1..._ 111.:149-154 (1978).
Belin, D., Vassalli, J.-D., Combepine, C., Godeau, F., Nagamine,
Y., Reich, E., Kocher, H.P., and Duvoisin, R.M., Cloning,
nucleotide sequencing and expression of cDNAs encoding mouse
urokinase-type plasminogen activator. ~ .s1..._ Biochem. l.!l..a:225-232
(1985).
Bonsall, R.W., and Hunt, S., Characteristics of interactions
between surfactants and the human erythrocyte membrane. Biochim.
Bioohys. Acta. 21!.9.:266-280 (1971 ).
Camiolo, S.M., and Greco, R., Plasminogen activator content of
human tumor and adjacent normal tissue measured with fibrin and
non-fibrin assays. Cancer ~ 1!.2.:1788-1794 (1986).
Campbell, E.J., Senior, R.M., McDonald, J.A. and Cox, D.L.,
Proteolysis by neutrophils • .s1..._ ~ Inyest. 1.Q.:845-852 ( 1982).
144

145

Carlsen, S.A., Ramshaw, I.A., and Warrington, R.C., Involvement of
plasminogen activator production with tumor metastasis in a rat
model. Cancer ~lL.!l.:3012-3016 (1984).
Carney, D.H., Scott, D.L., Gordon, E.A., and LaBelle, E.F.,
Phosphoinositides in mitogenesis: neomycin inhibits thrombinstimulated phosphoinositide turnover and initiation of cell
proliferation. ~ .!l.2_:479-488 ( 1985).
Christman, J.K., Silagi, S., Newcomb, E.W., Silverstein, S.C., and
Acs, G., Correlated suppression by 5-bromodeoxyuridine of
tumorigenicity and plasminogen activator in mouse melanoma cells.
Proc • .N..a.h. Acad. ~.Z.Z.:47-50 ( 1975).
Coleman, P., Kettner, C., and Shaw, E., Inactivation of the
plasminogen activator from HeLa cells by peptides of arginine
chloromethyl ketone. Biochim. Biophys. ~ 5.23.:41-51 (1979).
Colomb!, M., Barlati, S., Magdelenat, H., and Fiszer-Szafarz, B.,
Relationships between multiple forms of plasminogen activator in
human breast tumors and plasma and the presence of metastases in
lymph nodes. Cancer ~ ll:2971-2975 (1984).
Colton, T., in "Statistics in Medicine", Little, Brown and
Company, Boston, Mass. ( 1974).
Colucci, M., Giavazzi, R., Alessandri, G., Semeraro, N.,
Mantovani, A., and Donati, M.B., Procoagulant activity of sarcoma
sublines with different metastatic potential. Blood .51.:733-735
(1981).
Cooper, T.W., Eisen, A.Z., Stricklin, G.P., and Welgus, H.G.,
Platelet derived collagenase inhibitor: characterization and
subcellular localization. .IX,.Q£a.. Hs!i._ ~ ~ .a?_.:2779-2783
(1985).

146
Crowe, R., Ozer, H., and Rifkin, D.. In "Experiments with normal
and transformed cells: a laboratory manual for working with cells
in culture." Cold Spring Harbor Laboratory, Cold Spring Harbor,
New York ( 1978).
Dano, K., Andreasen, P.A., Grondahl-Hansen, J., Kristensen, P.,
Nielsen, L.S. and Skriver, L., Plasminogen activators, tissue
degradation, and cancer. ML. Cancer ~ !ll: 139-266 ( 1985).
Dano, K., Moller, V., Ossowski, L., and Nielsen, L.S.,
Purification and characteization of a plasminogen activator from
mouse cells transformed by an oncogenic virus. Biochim. Bioohys.
Acta • .21.3.: 542-555 ( 1980).
Davies, M., Barrett, A.J., Travis, J., Sanders, E., and Coles,
G.A., The degradation of human glomerular basement membrane with
purified lysosomal proteinases: evidence for the pathogenic role
of the polymorphonuclear leucocyte in glomerulonephritis. ~
~ Htl... MfilL....5..!l.:233-240 ( 1978).
DiStefano, J.F., Beck, G., Lane, B., and Zucker, S., Role of tumor
cell membrane-bound serine proteases in tumor-induced cytolysis.
Cancer ~ .!l.2.:207-218 ( 1982).
Esmon, C.T., Protein-C: biochemistry, physiology, and clinical
implications. Blood .22_:1155-1158 (1983).
Evers, J.L., Patel, J., Mateja, J.M., Schneider, S.L., Hobika,
G.H., Camiolo, S.M., and Markus, G., Plasminogen activator
activity and compostion in human breast cancer. Cancer~
~:219-226 ( 1982).
Falanga, A., and Gordon, S.G., Isolation and characterization of
cancer procoagulant: a cysteine proteinase from malignant tissue.
Bio chem. ll: 5558-5567 ( 1985).
Fidler, I.J., Selection of successive tumor lines for metastasis.
Nature ~:148-149 (1973).

147

Fidler, I.J., General considerations for studies of experimental
cancer metastasis. Methods Cancer ~ 15.:399-439 ( 1978).
Folkman, J., Langer, R., Linhardt, H.J., Haudenschild, C., and
Taylor, S., Angiogenesis inhibition and tumor regression caused by
heparin or a heparin fragment in the presence of cortisone.
Science 2Z1_:719-725 ( 1983).
Folkman, J., Tumor angiogenesis. ML. Cancer
(1985).

~

ll: 175-203

Frankfater, A. and Kuppy, T., Mechanism of association of Nacetyl-L-phenylalanyl-glycinal to papain. Biochem. 2.Q.:5517-5524
(1981).
Gasic, G.J., Viner, E.D., Budzynski, A.Z., and Gasic, G.P.,
Inhibition of lung tumor colonization by leech salivary gland
extracts from haementeria ghilianii. Cancer ~ ll:1633-1636
( 1983).
Gelehrter, T.D., and Sznycer-Laszuk, R., Thrombin induction of
plasminogen activator-inhibitor in cultured human endothelial
cells • .sl.._Clin. Inyest.11.:165-169 (1986).
Gilbert, L.C. and Gordon, S.G., Relationship between cellular
procoagulant activity and metastatic capacity of B16 mouse
melanoma variants. Cancer ~ ll:536-540 ( 1983).
Giraldi, T., Kopitar, M., and Sava, G., Antimetastatic effects of
a leukocyte intracellular inhibitor of neutral proteases. Cancer
~ 3.1.:3834-3835 ( 1977a).

Giraldi, T., Nisi, C., and Sava, G., Antimetastatic effects of NDiazoacetyl-glycine derivatives in C57BL mice.~~ Cancer
Inst. ,il:1129-1130 (1977b).

148

Giraldi, T., Nisi, C., and Sava, G., Lysosomal enzyme inhibitors
and antimetastatic activity in the mouse. Europ. ;_.._ Cancer
.11:1321-1323 ( 1977c).
Giraldi, T, Sava, G., Perissin, L., and Zorzet, S., Proteinases
and proteinase inhibition by cytotoxic and antimetastatic drugs in
transplantable solid metastasizing tumors in mice. Anticancer ~
5.:355-360 ( 1985a).
Giraldi, T., Sava, G., Perissin, L., Zorzet, s., Decorti, G., and
Steven, F.S., Tumor cell metastasis and surface neutral
proteinase: effects of antimetastatic and antitumor drugs.
Invasion Metastasis 5.:336-343 ( 1985b).
Goldfarb, R.H., and Quigley, J.P., Synergistic effect of tumor
virus transformation and tumor promoter treatment on the
production of plasminogen activator by chick embryo fibroblasts.
Cancer ~ .3.a:4601-4609 ( 1978).
Gordon, S.G., and Cross, B.A., A factor X-activating cysteine
protease from malignant tissue. ;.... .Qli.n._ Invest . .Ql.:1665-1671
( 1981).
Gordon, J.I., Sims, H.F., Edelstein, C., Scanu, A.M., and Strauss,
A.W., Extracellular processing of proapolipoprotein A-II in Hep G2
cell cultures is mediated by a 54-kDa protease immunologically
related to cathepsin B. ;.... lU.QL. Chem. ~:14824-14831 (1985).
Gorelik, E., Be re, W.W., and Herberman, R.B., Role of NK cells in
the antimetastatic effects of anticoagulation drugs • .Inta.. ;....
Cancer .3.1:87-94 (1984).
Granelli-Piperno, A., and Reich, E., A study of proteases and
protease inhibitor complexes in biological fluids. ;_.._ Exptl. Mfil!a_
.lll:223-234 ( 1979).

149

Hanada, K., Tamai, M., Adachi, T., Oguma, K., Kashiwagi, K.,
Chmura, S., Kominami, E., Towatari, T., and Katunuma, N.,
Characterization of three new analogs of E-64 and their
therapeutic application. In "Proteinase Inhibitors: Medical and
Biological Aspects," Katunuma, N., Umezawa, H., and Holzer, H.,
eds., pages 25-36, Japan Sci. Soc. Press, Tokyo ( 1983).
Hart, I.R., Selection and characterization of an invasive variant
of the B16 melanoma. AL. .J..... Pathol. .91.:587-600 ( 1979).
Harvey, H.A., Lipton, A., Albright, C., Katz, M., Troll, W., and
Rapp, F., Lack of inhibition of metastasis by proteolytic
inhibitors in an experimental herpes virus system. ~ .AJi1L
Assoc. Cancer~ 1.6.: 148 ( 1977).
Hilgard, P., Cancer and vitamin K. Lancet 403 ( 1977).
Honn, K.V., Cavanaugh, P., Evers, C., Taylor, J.D., and Sloane,
B.F., Tumor cell-platelet aggregation: induced by cathepsin B-like
proteinase and inhibited by prostacycline. Science 2.11:540-542
( 1982).
Honn, K. V., Steinert, B. W., Pilarski, S.M., Nelson, K.K., Sloane,
B.F., and Onoda, J.M., Effect of culture conditions on metastatic
potential of B16a tumor cells. ~ Amer. Assoc. Cancer ~
27: 30 ( 1 986) •
Huarte, J., Belin, D., and Vassalli, J.-D., Plasminogen activator
in mouse and rat oocytes: induction during meiotic maturation.
~43:551-558 (1985).
Ishii, H., Salem, H.H., Bell, C.E., Laposata, E.A., and Majerus,
P.W., Thrombomodulin, an endothelial anticoagulant protein, is
absent from the human brain. Blood .2.1:362-365 ( 1986).
Jimbow, K., Miyake, Y., Homma, K., Yasuda, K., Izumi, Y.,
Tsutsumi, A., and Ito, S., Characterization of melanogenesis and
morphogenesis of melanosomes by physiochemical properties of

150
melanin and melanosomes in malignant melanoma. Cancer Research
!!l.:1128-1134 (1984).
Jones, P.A., Hermon-Taylor, J., and Grant, D.A.W., Antiproteinase
chemotherapy of acute experimental pancreatitis using the low
molecular weight oligopeptide aldehyde leupeptin• .GY.t.z.1:939-943
( 1982).
Kabi Diagnostica, product information, Stockholm, Sweden.
Keiditsch, E. and Strauch, L., Collagenolytic activity in the
simple solid carcinoma of the breast, related to DNA content.
Verb. Dtsch. ~ Pathol. .il.:438-442 ( 1970).
Kennedy, W.P., and Schultz, R.M., Mechanism of association of a
specific aldehyde transition-state analogue to the active site of
alpha-chymotrypsin. Biochem. il:349-356 ( 1979).
Kirchheimer, J.C., Pfluger, H., Ritschl, P., Hienert, G. and
Binder, B.R., Plasminogen activator activity in bone metastases of
prostatic carcinomas as compared to primary tumors. Invasion
Metastasis .5.:344-355 ( 1985).
Kohga, S., Thromboplastic and fibrinolytic activities of ascites
tumor cells of rats, with reference to their role in metastasis
for ma ti on. .G..a.nn. Q.2.: 461-4 70 ( 197 8).
Kozlowski, K.A., Wezeman, F.H., and Schultz, R.M., Tumor cell
proteinase visualization and quantification using a fluorescent
transition-state analog probe. ~ ~ ~ ~ .fil..:1135-1139
( 1984).
Laemmli, U.K. Cleavage of structural proteins during the assembly
of the head of bacteriophage T4. Nature m_:680 ( 1970).
Laki, K., The purification of proteins: the action of thrombin on
fibrinogen. .A.r.Qb... Biochem. Biophys • .JZ.:317 ( 1951 ).

151

Lassen, M., Heat denaturation of plasminogen in the fibrin plate
method. A.Q.t..a.... Physiologica. Scandinayica. 21,:371-376 {1953).
Latner, A.L., Longstaff, E., and Turner, G.A., Anti-tumor activity
of aprotinin. fu:....L. Cancer .3.Q.:60-67 { 1974).
Lijnen, H.H., Zamarron, C., Blaber, M., Winkler, M.E., and Collen,
D., Activation of plasminogen by pro-urokinase. ~ .lU..Ql._ Chem.
fil:1253-1258 {1986).
Liotta, L.A., Hart, I.H.,eds., "Tumor Invasion and Metastasis,"
The Hague, Netherlands, Martinus Nijhoff Publishers (1982).
Liotta, L.A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C.M.
and Shafie, s., Metastatic potential correlates with enzymatic
degradation of basement membrane collagen. Nature ~:67-68
(1980a).
Liotta, L.A., Lee, C.W., and Morakis, D.J., New method for
preparing large surfaces of intact human basement membrane for
tumor invasion studies. Cancer l&.t.k 1J_: 141 ( 1980b).
Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Hand all. H.J.,
Protein measurement with the folin-phenol reagent. ~.lli.2.l.... Chem •
.19.3.:265-2 7 5 ( 1 951 ) •
Mackay, B., and Osborne, B.M., The contribution of electron
microscopy to the diagnosis of tumors. Pathobiology .Alm&. .a.:359-399
{1978).
Maniglia, C.A., Loulakis, P.P., and Sartorelli, A.C., Interference
with tumor cell-induced degradation of endothelial matrix on the
antimetastatic action of nafazatrom • ..slN.QI. 12.:739-744 (1986).

152
Markus, G., The role of hemostasis and fibrinolysis in the
metastatic spread of cancer. ~ Thromb. Hemostasis 1.Q.:61-70
( 1984).
Maruyama, I., and Majerus, P.W., The turnover of thrombinthrombomodulin complex in cultured human umbilical vein
endothelial cells and A549 lung cancer cells. JJ..... ~ Chem.
ZQQ.: 15432-154 38 ( 1985).
McLaughlin, M.E.H., Liener, I.E., and Wang, N., Proteolytic and
metastatic activities of clones derived from a methylcholanthreneinduced murine fibrosarcoma • .Q.i.n.._ ~ Metastasis 1.:359-371
( 1983).
Miner, K.M., Kawaguchi, T. Uba, G.W. and Nicolson, G.L., Clonal
drift of cell surface, melanogenic, and experimental metastatic
properties of in vivo selected, brain meninges-colonizing murine
B16 melanoma.Cancer ~li.2.:4631-4638 ( 1982).
Mira-y-Lopez, R., Reich, E., Stolfi, R.L., Martin, D.S., and
Ossowski, L., Coordinate inhibition of plasminogen activator and
tumor growth by hydrocortisone in mouse mammary carcinoma. Cancer
~ll:2270-2276 ( 1985).
Miskin, R., and Reich, E., Plasminogen activator: induction of
synthesis by DNA damage. ~ 1..2.:217-224 ( 1980).
Mort, J.S., Recklies, A.D., and Poole, A.R., Characterization of a
thiol proteinase secreted by malignant human breast tumors.
Biochem. Biophvs • .kt.a ill.:134-143 (1980).
Mosesson, M.W., The purification of human fibrinogen free of
plasminogen. Biochem. Biophys. Atl.a._ .5.1.:204 ( 1962).
Nakagawa, H., Aihara, K., and Tsurufuji, s., The role of cathepsin
B1 in the collagen breakdown of carrageenin granuloma in rats. JJ.....
Biochem• .B.1_:801-804 (1977).

153

Nakajima, M., Irimura, T., DiFerrante, D., and Nicolson, G.,
Heparan Sulfate Degradation: Relation to tumor invasive and
metastatic properties of mouse B16 melanoma sublines. Science
z.z..Q.:611-613 ( 1983).
Newcomb, E.W., Silverstein, S.C., and Silagi, S., Malignant mouse
melanoma cells do not form tumors when mixed with cells of a nonmalignant subclone: relationship between plasminogen activator
expression by the tumor cells and the host's immune response. ~
Cell. Physiol. ..9..5.:169-178 (1978).
Nicolson, G.L., Winkelhake, J.L., and Nussey, A.C., in
"Fundamental Aspects of Metastasis" (Weiss, L., ed.), 291-303,
Amsterdam, North-Holland Publishing Co (1976).
Nicolson, G.L., Organ colonization and the cell-surface properties
of malignant cells. Biochim. Biophys • .A.Q1a, .2..25.:113-176 (1982).
Ossowski, L., Quigley, J.P., and Reich, E., Fibrinolysis
associated with oncogenic transformation. ~ JliQl.... Chem. lli.:43124320 ( 1974).
Ossowski, L., Biegel, D., and Reich, E., Mammary plasminogen
activator:correlation with involution, hormonal modulation and
comparison between normal and neoplastic tissue. ~.16..:929-940
( 1979).
Ossowski, L., and Reich, E., Antibodies to plasminogen activator
inhibit human tumor metastasis. ~ .3,i:611-619 (1983).
Ossowski, L., and Wilson, E., The role of plasminogen activator in
tumor invasion and metastasis. (abs.) ~ ~ Biochem. Supplement
10A page 234 (1986).
Paranjpe, M., Engel, L., Young, N., and Liotta, L.A., Activation
of human breast carcinoma collagenase through plasminogen
activator. ~ ~ z.Q..:1223-1231 (1980).

154

Patel, A.H., Ahsan, A., Suthar, B.P., and Schultz, R.M.,
Transition-state affinity chromatography of trypsin-like
proteinases with dipeptidyl argininal ligands. Biochem. Biophys.
Atla ~= 321-330 ( 1983).
Pearlstein, E., Ambrogio, C., Gasic, G., and Karpatkin, s.,
Inhibition of the platelet-aggregating activity of two human
adenocarcinomas of the colon and an anaplastic murine tumor with a
specific thrombin inhibitor, dansylarginine N-(3-ethyl-1,5pentanediyl)amide. Cancer ~ fil.:4535-4539 ( 1981 ).
Persky, B., Ostrowski, L.E., Pagast, P., Ahsan, A., and Schultz,
R.M., Inhibition of proteolytic enzymes in the .in vitro amnion
model for basement membrane invasion. Cancer ~Accepted for
publication, 1986.
Persky, B., and Chmielewski, G.W., A comparative study on .in yitro
invasion rates by melanoma cells in the human amniotic basement
membrane model versus ill .vim tumor nodule formation in C57BL6
mice. Submitted, 1986.
Phillips, H.J., chapter 3 in "Tissue Culture:methods and
applications", Kruse, P.F., and Patterson, M.K., eds., Academic
Press ( 1973).
Poole, A.R., Tiltman, K.J., Recklies, A.D., and Stoker, T.A.M.,
Differences in secretion of the proteinase cathepsin B at the edge
of human breast carcinomas and fibroadenomas. Nature 213.:545-547
(1978).
Poste, G., and Flood, M.K., Cells transformed by temperturesensitive mutants of Avian Sarcoma virus cause tumors J.nl!iv.Q. at
permissive and non-permissive tempertures. ~ ll.:789-800 ( 1979).
Quigley, J.P., Phorbol ester-induced morphological changes in
transformed chick fibroblasts: evidence for direct catalytic
involvement of plasminogen activator. ~ ll.:131-141 (1979).

155

Quigley, J.P., Proteolytic enzymes of normal and malignant cells.
In Hynes, R.O. ed., "Surfaces of Normal and Malignant Cells," New
York, N.Y., Wiley and Sons (1979).
Quigley, J., Cramer, E., Fairbairn, S., Gilbert, R., Lacovara, J.,
Ojakian, G., and Schwimmer, R., Interaction of malignant
cells with substrata: adhesion, degradation and migration. In
Honn, K.V., Powers, W.E., and Sloane, B.F., eds., "Mechanisms of
Cancer Metastasis: potential therapeutic implications," Boston,
Mass., Marti nus Ni jhoff ( 1 986).
Rajput, B., Degen, S.F., Reich, E., Waller, E.K., Axelrod, J.,
Eddy, R.L., and Shows, T. B., Chromosomal locations of human
tissue plasminogen activator and urokinase genes. Science 2.3Q.:672674 (1985).
Recklies, A.D., Tiltman, K.J., Stoker, T.A.M., and Poole, A.R.,
Secretion of proteinases from malignant and nonmalignant human
breast tissue. Cancer ~ .!LQ.:550-556 ( 1980).
Recklies, A.D., White, c., Mitchell, J., and Poole, A.R.,
Secretion of a cysteine proteinase from a hormone independant cell
population of cultured explants of murine mammary gland. Cancer
~ .!l.5..:2294-2301 (1985).
Recklies, A.D., and Mort, J.S., Characterization of a cysteine
proteinase secreted by mouse mammary gland. Cancer ~ l!.5_:23022307 ( 1985).
Rickles, F.R., and Edwards, R.L., Activation of blood coagulation
in cancer: Trousseau's syndrome revisited. Blood ,22.:14-31 (1983).
Rifkin, D.B., Proteins regulating cellular invasion. (abs.)
Biochem. Supplement 10A page 235 (1986).

~

Rijken, D.C., and Groeneveld, E., Isolation and functional

~

156
characterization of the heavy and light chains of human tissuetype plasminogen activator. k. ,W..Ql.,. Chem. z.2..1..:3098-3102 (1986).
Roblin, R.O., Young, P.L. and Bell, T.E., Concomitant secretion by
transformed SVWI38-VA13-2RA cells of plasminogen activator(s) and
substance(s) which prevent their detection. Biochem. Biophys. ~
Comm • .B.2_:165-172 (1978).
Rosenthal, S.L., Zucker, D., and Davidson, R.L., Dissociation of
plasminogen activator from the transformed phenotype in a 5bromodeoxyuridine dependant mutant of syrian hamster melanoma
cells. J!.a.. Cell. Physiol. .95_:275-286 ( 1978).
Saito, D., Sawamura, M., Umezawa, K., Kanai, Y., Furihata, C.,
Matsushima, T., and Sugimura, T., Inhibition of experimental
blood-borne lung metastasis by protease inhibitors. Cancer ~
l!Q.:2539-2542 ( 1980).
Salminen, A., Kihlstrom, M., and Vihko, V., Acid proteolytic
activities in mouse liver and muscle tissues after treatment with
protease inhibitor leupeptin. Comp. Biochem. Physiol. 1.2.:93-95
( 1984).
Schirrmmacher, V., Cancer metastasis: Experimental approaches,
theoretical concepts, and impacts for treatment stratagies. ~
Cancer ~.!LQ: 1-73 ( 1985).
Sher, J.H., Stracher, A., Shafiq, S.A., and Hardy-Stashin, J.,
Successful treatment of murine muscular dystrophy with the
proteinase inhibitor leupeptin. ~ ~ ~ ~1.a:7742-7744
( 1981 ) •
Shimada, K., and Ozawa, T., Release of heparan sulfate
proteoglycans from cultured aortic endothelial cells by thrombin.
Thromb. ~ .3..9.: 387-397 ( 1985).
Skriver, L., Larsson, L., Kielberg, V., Nielsen, L.S., Andresen,
P.B., Kristensen, P. and Dano, K., Immunocytochemical localization

157
of urokinase-type plasminogen activator in Lewis Lung Carcinoma.

L. ~Biol. !1!1:752-757 ( 1984).
Sloane, B.F., Dunn, J.R. and Honn, K.V., Lysosomal cathepsin B:
Correlation with metastatic potential. Science Zl.a:1151-1153
( 1981).
Sloane, B.F., Bajkowski, A.S., Day, N.A., Honn, K.V., and
Crissman, J.D., Purification and properties of a cathepsin B-like
enzyme from human tumors: comparison with cathepsin B isolated
from human liver and spleen. (abs.) ~Am._ Assoc. Cancer ~
25_:4 (1984).
Sloane, B.F. and Honn, K.V., Cysteine proteinases and metastasis.
Cancer Metastasis Reviews ,1:24 9-26 3 ( 1984 ).
Sloane, B.F., Rozhin, J., Ryan, R.E., Lah, T.T., Day, N.A.,
Crissman, J.D., and Honn, K.V., Cathepsin B-like cysteine
proteinases and metastasis. In Honn, K.V., Powers, W.E., and
Sloane, B.F., eds., "Mechanisms of Cancer Metastasis: potential
therapeutic implications," Boston, Mass., Martinus Nijhoff (1986).
Steven, F.S., Griffin, M.M., and Itzhaki, s., Inhibition of free
and bound trypsin-like enzymes. Em:._ ~ Biochem . .1Z2_:311-318
( 1982).
Strauli, P., Barrett, A.J., Baici, A. eds., "Proteinases and Tumor
Invasion," New York, N. Y., Raven Press ( 1980).
Stryer, L., in "Biochemistry," pages 157-185, San Francisco,
Calif., W.H. Freeman and Co. (1981).
Sutherland, J.H.R., and Greenbaum, L.M., Paradoxical effect of
leupeptin .1.n .v.ivQ. on cathepsin B activity. Biochem. Biophys. ~
Comm, ..11Q:332-338 (1983).
Sylven, B., Snellman, 0., and Strauli, P., Immunofluorescent

158
studies on the occurence of cathepsin B1 at tumor cell surfaces.
Virchows ~ ~ ~ ..ea.th&. 11.:97-112 ( 1974).
Takenaga, K., Enhanced metastatic potential of cloned lowmetastatic Lewis Lung carcinoma cells treated .in vitro with
dimethyl sulfoxide. Cancer ~ ll:1122-1127 (1984).
Tanaka, K., Ikegaki, N., and Ichihara, A., Purification and
characterization of hemoglobin-hydrolyzing acidic thiol protease
induced by leupeptin in rat liver • .sL.. .lli.Q.L_ Chem. z.5.2.:5937-5944
( 1984).
Tanaka, N., Ogawa, H., Kinjo, M., Kohga, S., and Tanaka, K.,
Ultrastructural study of the effects of transexamic acid and
urokinase on metastasis of Lewis Lung carcinoma. ~ .sL.. Cancer
!.6_:428-435 ( 1982).
Tanaka, W., Absorption, distribution, metabolism, and excretion of
leupeptin. In "Proteinase Inhibitors: Medical and Biological
Aspects," Katunuma, N., Umezawa, H., and Holzer, H., eds., pages
17-24, Japan Sci. Soc. Press, Tokyo ( 1983).
Terranova, V.P., Liotta, L.A., Russo, R.G., and Martin, G.R., Role
of laminin in the attachment and metastasis of murine tumor cells.
Cancer~ liZ.:2265-2269 (1982).
Thorgeirsson, V.P., Liotta, L.A., Kalebic, T., Margulies, I.M.,
Thomas, K., Rios-Candelore, M., and Russo, R.G., Effect of natural
protease inhibitors and a chemoattractant on tumor cell invasion
in vitro. ~ .Q.2.: 104 9-1054 ( 1982).
Tohgo, A., Tanaka, N.G., and Ogawa, H., Platelet-aggregating
activities of metastasizing tumor cells. Invasion Metastasis 5.:96105 (1985).
Turner, G.A., and Weiss, L., Analysis of aprotinin-induced
enhancement of metastasis of Lewis Lung tumors in mice. Cancer
~ .!U.:2576-2580 ( 1981 ).

159

Unkeless, J.C., Tobia, A., Ossowski, L., Quigley, J.P., Rifkin,
D.B., and Reich, E., An enzymatic function associated with
transformation of fibroblasts by oncogenic viruses • .sL.. ~ ~
1.11: 85-111 ( 1973).
Vassalli, J.D., Baccino, D., and Belin, D., A cellular binding
site for the Mr 55,000 form of the human plasminogen activator,
urokinase. ~Cell. Biol. .1.QQ:86-92 ( 1985).
Wang, B.S. McLoughlin, G.A., Richie, J.P. and Mannick, J.A.,
Correlation of the production of plasminogen activator with tumor
metastasis in B16 mouse melanoma cell lines. Cancer ~ !.Q.:288292 (1980).
Werb, Z., and Aggeler, J., Proteases induce secretion of
collagenase and plasminogen activator by fibroblasts. ~Hat._
Acad. ~15.:1839-1843 (1978).
Werb, Z., Banda, M.J., and Jones, P.A., Degradation of connective
tissue matrices by macrophages • .sL.. ~ ~ 1.5Z:1340-1357 (1980).
Wexler, H., Accurate identification of experimental pulmonary
metastases . .slli.Q.I.32.:641-643 (1966).
Wilson, E.L. and Dowdle, E., Secretion of plasminogen activator by
normal, reactive and neoplastic human tissues cultured ..i..n vitro .
.I.n.t......~ Cancer Z.Z.:390-399 ( 1978).
Wilson, E.L., Becker, M.L.B., Hoal, G. and Dowdle, E.B., Molecular
species of plasminogen activators secreted by normal and
neoplastic human cells. Cancer ~ !.Q.:933-938 ( 1980).
Wolf, B.A., and Goldberg, A.R., Lack of correlation between
tumorigenicity and level of plasminogen activator in fibroblasts
transformed by Rous Sarcoma virus. ~Hat._~~ 15_:49674971 (1978).

160

Wood, J.S., Holyoke, E.D., Clason, W.P.C., Sommers, S.C., and
Warren, S., An experimental study of the relationship between
tumor size and number of lung metastases. Cancer 1.:437-443 {1954).
Zucker, S., Lysik, R.M., Ramamurthy, N.S., Golub, L.M., Wieman,
J.M., and Wilkie, D.P., Diversity of melanoma plasma membrane
proteinases: inhibition of collagenolytic and cytolytic activities
by minocycline. .slli.Ql. 15.:517-525 { 1985).

APPENDIX A

162

APPENDIX A

/°'
/c-c

H,
HOOC

/CONHCHCONH~H

'H

CH 2

,.C!I

CH 2

,C!f 2

CH CH CH CH
3
3
3
3
(L-form)

(L-Leu)

Ep-475

j2

H3

~'113

~

c;::mi;
NH

<f~>3

~~NH-CH-CO-NH-CH-COO

APPENDIX B

164

APPENDIX B

Several variations of the basic procedure for collecting
serum-free conditioned medium (SFCM) from the B16 melanoma were
attempted. The first of these consisted of growing the cells in
cycles of complete medium and serum-free medium (SFM). Thus cells
were grown in complete medium until semi-confluent (as observed
under the light microscope), washed in 5 ml of PBS twice,
incubated in SFM for one day, after which the SFCM was collected and
the cells were reincubated in complete medium. The cells
maintained a healthy morphology under these conditions, but
continued to increase in density when incubated in complete
medium. When washed in PBS and recycled in SFM for a second day,
large numbers of the cells detached from the tissue culture
flask and a large quantity of cellular debris was evident in the
medium. Therefore this procedure was not used, as the floating
cells and debris was taken as an indication of cell lysis and
death, which would release many proteolytic enzymes and other
contaminants which would complicate the purification scheme.
Flasks were also cycled in SFM for two days before being
reincubated in complete medium, followed by another cycle of SFM
with similar results.
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A second possibility was to select for a population of cells
which would be able to be maintained in SFM for extended lengths
of time. This was attempted by culturing B16-F10 cells in complete
medium until semi-confluent and then refeeding them only in SFM.
These cultures approached confluency and then large numbers of the
cells would release from the surface of the flask. These were
removed with media changes and the cells remaining attached were
refed in SFM. After several passages, the remaining cells (which
were very scarce and no longer seemed to be replicating), were
reincubated with medium containing calf serum (5% or 10%). The
cells proliferated in the complete medium until a semi-confluent
state was again reached, and then the selection procedure of
growth in SFM only was repeated. The results were very similar to
the first selection, with very few cells actually remaining
attached (<10%). This procedure was abandoned for the following
reasons: i) a truly stable population of cells capable of longterm culture in SFM was not identified, ii) the cells which did
survive in SFM for several cycles did not appear morphologically
"healthy" (small, more spindly) when compared to B16-F10 grown in
complete medium, iii) when the SFCM from these cells was examined
by polyacrylamide gel electrophoresis and zymography, although the
amount of protein was very low, the amount of PA activity detected
was also low.
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The use of serum supplements was explored as a third
possibility for obtaining larger amounts of SFCM efficiently.
Ultroser G (LKB, Bromma, Sweden) was used for these studies because
many cell types have been successfully cultured using this as a
serum supplement. Ultroser G contains necessary growth and
adhesion factors, hormones, binding proteins, vitamins, and
mineral trace elements. B16-F10 cells grown to semi-confluency
were adapted to growth in Ultroser G by first replacing one-half
of their medium with SFM containing 1% Ultroser G. This was
completely replaced with 1% Ultroser G in SFM after 24 hr. Under
these conditions, cells maintained a healthy morphology, however
the cultures did not increase in number, even with daily
refeedings. Increasing the Ultroser G content to 2% resulted in
increased growth of the cultures. However, this procedure was also
found to be unsuccessful because of the following considerations:
i) When cultured in Ultroser G, the B16-F10 cells failed to
produce notable amounts of melanin. This was a significant change
from the cellular phenotype observed when cultured in complete
medium. It was desireable to study the PA produced by the melanoma
cells under conditions as close as possible to those used for
preparing the cells for the .in vivo studies. Ultroser G was thus
not suitable.
ii) Electrophoresis and zymography of Ultroser G conditioned
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medium revealed a significant amount of PA activity, but the
activity was smeared by a large protein band and migrated slightly
below the position of mouse UK. This difference was not explored
further, but again indicated that the change in culture conditions
was having an effect on the desired product, PA.
iii) It was not possible to maintain cells in Ultroser G for
truly extended lengths of time. Thus the procedure was not much
more efficient than growing the B16-F10 cells in complete media.
In addition, Ultroser G became unavailable for import shortly
after these studies began.
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Nodules in mouse lungs which contained melanin were easily
distinguishable from the normal tissue, and because of the
presence of melanin, were identified as melanomas arising from the
injected B16-F10 cells. However, the appearance of amelanotic
nodules in some experiments required the use of another technique
to verify that the nodules were in fact melanomas. As discussed by
Mackay and Osborne ( pg.379, 1978), the presence of premelanosomes
as visualized by electron microscopy is definitive evidence which
allows the tissue to be positively identified as arising from a
melanoma. With the kind and generous help of Dr. Bruce Persky,
samples of both amelanotic and melanotic nodules were examined by
transmission electron microscopy, by techniques previously
described (Persky and Chmielewski, 1986;

Persky~ .s.l_.,

1986) and

outlined below.
Mice were sacrificed by cervical dislocation and the lungs
were quickly removed, dissected free of other tissues, and rapidly
rinsed in phosphate buffered saline to remove debris. Samples
containing amelanotic and melanotic nodules were then carefully
cut from the lungs in cubes (1 mm3 or smaller) and immediately
immersed in modified Karnovsky fixative (1% paraformaldehyde,
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1.25% glutaraldehyde pH 7.4) for 24 hr. The samples were then
postfixed in 2% Os04 buffered in 0.072 N cacodylate buffer at pH
7.4 for 1 hr. After dehydration in increasing concentrations of
ethanol, samples were embedded in Epon. Thin sections were cut
from the samples and stained with uranyl acetate and lead citrate.
Grids were then examined with a Hitachi H-600 transmission
electron microscope.
Stage III premelanosomes were observed in all samples,
therefore verifying that the nodules observed were melanomas.
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